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ABSTRACT: 
 
 Since 1971, when McComas described the first neurophysiological technique for 
the estimation of the number of motor units in a muscle (MUNE), several other methods 
have been developed over the following decades. Each technique has its own 
advantages and disadvantages, but at the moment none of them has gathered enough 
consensus to arise as a predominant method. 
 In neurodegenerative diseases, such as Amyotrophic Lateral Sclerosis (ALS), the 
possibility of monitor the loss of motor units throughout the course of the disease would 
be of the outmost importance, in particular in the context of clinical trials. In present 
time, the neurophysiological methods that we have at our disposal are not the most 
adequate ones to follow the progression in this kind of diseases. 
 Motor unit number estimation techniques would be an excellent measure of the 
loss of motor units in these patients. However, all of the techniques described have 
limitations that prevented them to become a primary endpoint in clinical trials. 
 In this work, we describe a new technique for estimating the number of motor 
units in a muscle that it's called Motor Unit Number Index (MUNIX). We assess test-
retest variability and evaluate the suitability of this technique as a potential marker of 
disease progression in ALS. 
 A group of 15 normal subjects was studied two times by two different raters to 
assess intra and inter rater variability. Overall reliability results were reasonably good 
(MUNIX megascore ICC=0.740). 
 A group of 11 ALS patients was studied over 9 to 12 months at regular intervals. 
We compared MUNIX to other known disease progression markers such as compound 
muscle action potential (CMAP), ALSFRS-R and muscle strength, and to another 
MUNE technique. MUNIX declined significantly with time (p < 0.001) and had higher 
progression rates than ALSFRS-R and muscle strength (p = 0.005). 
 We also compared MUNIX with multiple point stimulation MUNE in the 
abductor digiti minimi of ALS patients. MUNIX showed a significantly higher 
progression rate, with a steeper decline than that other MUNE method, showing that it 
can a suitable technique for estimating the number of motor units and to monitor its loss 
in the course of neurodegenerative diseases. 
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RESUMO: 
Desde 1971, quando McComas descreveu o primeiro método neurofisiológico 
para estimar o número de unidades motoras num músculo (MUNE), vários outros 
métodos foram desenvolvidos. Cada técnica possui as suas vantagens e desvantagens 
mas, até agora, nenhuma reuniu aceitação generalizada de forma a se assumir como o 
método predominante. 
Em doenças neurodegenerativas, como a Esclerose Lateral Amiotrófica (ELA), a 
possibilidade de avaliar a perda de unidades motoras durante o curso da doença é de 
extrema importância, particularmente em ensaios clínicos. Actualmente, os métodos 
neurofisiológicos de que dispomos não são os mais adequados para quantificar a 
progressão deste tipo de doenças. 
As técnicas de estimativa de unidades motoras assumem-se como uma excelente 
medida de avaliação de perda de unidades motoras nestes doentes. No entanto, todas 
estas técnicas apresentam limitações que as impedem de serem consideradas como um 
endpoint primário em ensaios clínicos. 
Neste trabalho, descrevemos um novo método para estimar o número de 
unidades motoras num músculo, denominado Motor unit number index (MUNIX). 
Fomos avaliar a variabilidade intra- e inter-utilizador, bem como a sua adequação como 
um potencial marcador de progressão de doença na ELA. 
Um grupo de 15 indivíduos saudáveis foi avaliado duas vezes por dois 
avaliadores independentes de forma a avaliar a reprodutibilidade do método. 
Globalmente, a reprodutibilidade do método foi bastante satisfatória (ICC Megascore 
MUNIX=0.740). 
Um grupo de 11 doentes com ELA, foi avaliado durante 9 a 12 meses em 
intervalos regulares. Comparámos o MUNIX com outras medidas de progressão da 
doença já descritas, tais como o potencial de acção muscular composto (CMAP), a 
escala ALFRS-R e o grau de força muscular, assim como com outro método de 
estimativa de unidades motoras. O MUNIX progrediu significativamente ao longo do 
tempo (p < 0.001) e teve uma maior taxa de progressão comparativamente à ALSFRS-R 
e ao grau de força muscular (p = 0.005). 
Posteriormente, comparámos o MUNIX com o multiple point stimulation 
MUNE no músculo abdutor do 5º dedo nos doentes de ELA. O MUNIX revelou uma 
taxa de progressão significativamente maior, com um declínio mais linear do que este 
outro método de MUNE, demonstrando que é uma técnica adequada para estimar o 
número de unidades motoras e avaliar a sua perda ao longo do curso de doenças 
neurodegenerativas. 
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1. INTRODUCTION 
 
 1.1 Motor unit 
 History and anatomical studies 
 The first time the concept of “motor unit” was mentioned in the literature was in 
1925, by Sir Charles Sherrington (Liddell and Sherrington, 1925). He defined motor 
unit as the “axon-motoneuron and its adjunct muscle fibers” and drew attention for its 
all-or-none responsiveness. Four years later, Sherrington (1929) redefined motor unit as 
“the axon and the group of muscle fibers it activates. Each such "motor unit" has 
centrally, of course, a nerve-cell of which a group or "pool" represents the muscle in the 
spinal cord”. In fact, over 80 years have passed since the dawn of this groundbreaking 
concept, and we still define motor unit as the aggregate of an axon and the muscle fibers 
it innervates. 
 Eccles and Sherrington (1930), with their optical recording system, were the first 
to investigate the number of motor units in muscles of the cat hindlimb. The dorsal 
nerve root ganglia were excised and, after the time needed for the sensory fibers to 
degenerate has passed, the surviving myelinated fibers were added up and assumed to 
be motor. They obtained values around 640 for the semitendinosus, 430 for the medial 
gastrocnemius and 250 for the soleus. Albeit this pioneer study, and even taken in 
consideration the recognition of the distribution of myelinated nerve fibers in two 
groups, the authors failed to distinguish between the thinner (γ) axons that supply the 
small muscle fibers in the muscle spindles, and the thicker (α) axons that innervate 
skeletal muscle fibers. Only a few years later (Leksell, 1945) this problem was 
acknowledged. 
 The first anatomical studies of human motor units were by Feinstein (Feinstein 
et al., 1955). Although it was a tedious task to count stained cross-sections of large 
myelinated fibers from cadavers‟ nerves, the greatest difficulty was to decide the 
proportion of α-motor and sensory axons. After comparing the counts made with a 
cross-section of a patient who died after having a severe case of poliomyelitis, the 
authors proposed the ratio of 60:40 (α-motor/sensory axons) 
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 This ratio was used in the vast majority of anatomical studies that were reported 
in the following decades. In table 1 (Sica and McComas, 2003) we can see an overall of 
anatomic studies in various human muscles 
  
Table 1: Anatomical estimation of numbers and sizes of motor units in various human muscles 
(Sica and McComas, 2003) 
Muscle Reference Nº of motor units Muscle fibers/unit 
External rectus Feinstein et al. (1955) 2970 9 
Superior rectus (2) Christensen (1959) 1779 23 
Temporalis Carlsöö (1958) 1331 936 
Masseter (2) Carlsöö (1958) 1425 2373 
Platysma Feinstein et al. (1955) 1096 25 
Biceps Brachii Christensen (1959) 3552 163 
Brachioradialis Feinstein et al. (1955) 333 >410 
Opponens Pollicis Christensen (1959) 6047 13 
Thenar (median n.) Lee et al. (1975) 203 -- 
First dorsal interosseous Feinstein et al. (1955) 119 340 
First lumbrical Feinstein et al. (1955) 96 108 
Abductor digiti minimi (10) Santo Neto et al. (1985) 380 190 
Opponens digiti minimi (4) Carvalho et al. (1988) 158 100 
Flexor digiti minimi (10) Santo Neto et al. (1998) 130 108 
Sartorious (2) Christensen (1959) 740 300 
Rectus femoris Christensen (1959) 609 305 
Gracilis Christensen (1959) 275 527 
Semitendinosus Christensen (1959) 712 713 
Med. + lat. Gastrocnemii Christensen (1959) 778 2037 
Med. Gastrocnemius Feinstein et al. (1955) 579 1934 
Tibialis anterior Feinstein et al. (1955) 445 562 
Plantaris (5) Carvalho (1976) 204 372 
Note: Unless otherwise indicated, values derived from single muscle 
 
 Although the results of these studies are more or less similar, they are different 
enough to prevent the designation of a true standard value for the number of motor units 
in human muscles. On top of that, is now clear from other anatomical studies (Boyd and 
Davey, 1968), that the ratio of motor to sensory axons varies greatly between muscles. 
Therefore, the 60:40 ratio proposed by Feinstein is, at the best, uncertain. 
MUNIX – A new method of motor unit number estimation 
Neurosciences Master, 2012  11 
 Nevertheless, these histological studies can serve as baseline comparison for the 
physiological motor unit number estimation (MUNE) techniques that have been 
developed. 
 
  Physiology of the motor units 
 Skeletal muscle fibers are innervated by large myelinated nerve fibers derived 
from alpha motor neurons (α-MNs) of the spinal cord and brainstem. The cell bodies of 
the α-MNs are localized in the anterior gray horns in the spinal cord or in the motor 
nuclei in the brainstem. The axon of each motor neuron exits the spinal cord through a 
ventral root (or through a cranial nerve from the brainstem) and traverses progressively 
smaller branches of peripheral nerves until it enters the muscle it controls. As each 
myelinated fiber enters a skeletal muscle, it branches many times, each branch 
terminating on a muscle fiber at a site named neuromuscular junction. 
 Each motor unit innervates exclusively muscle fibers of the same type. The 
number of branches depends on the size of the motor unit and can go from 100 up to 
1000 muscle fibers scattered over the muscle, depending mostly on the function of this 
muscle. In muscles with more refined motions, less muscle fibers each unit innervates, 
and vice-versa. 
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 Near the motor end-plate, the nerve branch ends as a naked axon (presynaptic 
membrane), with no myelin surrounding it, since the Schwann cells serve only as a cap, 
never projecting into the synaptic cleft. At this point, the axon is slightly expanded, and 
has many mitochondria and acetylcholine (ACh) vesicles. 
 At this site, the surface of the muscle fiber is slightly elevated due to the 
accumulation of granular sarcoplasm and the presence of numerous mitochondria and 
nuclei. 
 
 
Figure 1 
A - Photomicrograph of a motor end plate showing terminal branching of a nerve fiber. 
B - Electron micrograph of a terminal axon at a motor end-plate 
Clinical Neuroanatomy; Richard Snell, 2010 
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 When an action potential travels through the nerve and arrives at the presynaptic 
membrane, Ca
2+
 enter the axon, via Ca
2+
 voltage dependent channels, and begins a 
cascade that leads to the release of ACh to the synaptic cleft. 
 The ACh then binds to postsynaptic-nicotinic-type ACh-gated channels and Na
+
 
ions flow into the muscle cell giving origin to an action potential that spreads along the 
sarcolemma into the contractile myofibrils. This leads to the release of Ca
2+
 ions from 
the sarcoplasmic reticulum, which, in turn, causes the muscle to contract. 
Figure 2: 
A - A skeletal neuromuscular junction 
B - Enlarged view of a muscle fiber showing the terminal naked axon 
Clinical Neuroanatomy; Richard Snell, 2010 
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 Since a single action potential in an α-motor neuron can activate dozens, or even 
hundreds, of muscle fibers synchronously, the resulting currents sum to generate an 
electrical signal that is easily recorded outside the muscle itself. The superficial 
recording of this large electrical field, generated by the activation of the muscle fibers, 
is the basis of Electromyography (EMG), Nerve conductions studies (NCS) and MUNE 
techniques. 
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 1.2 Amyotrophic Lateral Sclerosis 
 Despite the fact that MUNE techniques could be useful in many 
neurodegenerative diseases like Amyotrophic Lateral Sclerosis (ALS), Spinal muscular 
atrophy (SMA), Poliomyelitis or even different types of Peripheral neuropathies, the 
focus of this work will be on ALS. 
  
 Definition 
 ALS, also known as Motor neuron disease (MND) or Lou Gehrig's disease, is a 
fatal neurodegenerative disorder of the motor system, characterized by progressive 
muscular paralysis reflecting degeneration of motor neurons is the primary motor 
cortex, brainstem and spinal cord (Wijesekera and Leigh, 2009). The term 
"Amyotrophy" represents the loss of muscle fibers due to denervation caused by 
degeneration of the anterior horn cells. "Lateral sclerosis" represents the replacement of 
the corticospinal tract by gliosis as the result of cortical motoneurons degeneration 
(Rowland and Shneider, 2001). 
  
 Diagnostic and classification criteria 
 The diagnosis of ALS can be challenging. Not only there are a number of 
potentially mimicking diseases (e.g. Cervical radiculomyelopathy), but also there is no 
specific biomarker. Therefore, the diagnosis is based on a collection of some very 
characteristic clinical findings in combination with examinations to document signs of 
lower and/or upper motor neuron signs and to rule out other conditions. 
 The first set of clinical criteria for the diagnosis of ALS was developed in 1994 
by the World Federation of Neurology (Brooks, 1994), the "El Escorial" diagnostic 
criteria. These criteria were revised a few years later (Brooks et al., 2000), the "Airlie 
House" criteria. According to this last set of criteria, patients can be classified as 
summarized in table 2 (Brooks et al., 2000). 
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Table 2: Summary of Revised El Escorial Research Diagnostic Criteria for ALS (Wijesekera and Leigh, 2009) 
 
The diagnosis of ALS requires: 
1 Evidence of LMN degeneration by clinical, electrophysiological or neuropathological examination; 
2 Evidence of UMN degeneration by clinical examination, and 
3 Progressive spread of symptoms or signs within a region or to other regions, as determined by history or 
examination, 
 
Together with the absence of: 
[1] Electrophysiological and pathological evidence of other disease that might explain the signs of LMN and/or UMN 
degeneration, and 
[2] Neuroimaging evidence of other disease processes that might explain the observed clinical and electrophysiological 
signs 
 
Categories of clinical diagnostic certainty on clinical criteria alone 
 
Definite ALS 
• UMN signs and LMN signs in 3 regions 
 
Probable ALS 
• UMN signs and LMN signs in 2 regions with at least some UMN signs rostral to LMN signs 
 
Probable ALS – Laboratory supported 
• UMN signs in 1 or more regions and LMN signs defined by EMG in at least 2 regions 
 
Possible ALS 
• UMN signs and LMN signs in 1 region (together), or 
• UMN signs in 2 or more regions 
• UMN and LMN signs in 2 regions with no UMN signs rostral to LMN signs 
 
UMN (Upper Motor Neuron) signs: clonus, Babinski sign, absent abdominal skin reflexes, hypertonia, loss of 
dexterity. 
LMN (Lower Motor Neuron) signs: atrophy, weakness. If only fasciculation: search with EMG for active denervation. 
Regions reflect neuronal pools: bulbar, cervical, thoracic and lumbosacral. 
 
 In 2008, a consensus meeting was held by a group of experts and a new set of 
rules to define the electrophysiological diagnosis of ALS was recommended, the Awaji 
criteria (de Carvalho, 2008). These criteria simplified the previous ones and highlighted 
the importance of the fasciculation potentials in the diagnosis of ALS. Table 3 
summarizes the modifications introduced by the recent Awaji recommendations. 
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Table. 3 – Comparison between the revised El Escorial criteria and the Awaji set of 
recommendations 
 
1. Principles of the Revised El Escorial Criteria 
The diagnosis of ALS requires 
 
A: evidence of lower motor neuron (LMN) loss (reduced interferential pattern on full contraction and 
increased firing rate) 
B: evidence of reinnervation (motor units of large amplitude and longer duration) 
C: fibrillation and sharp-waves 
 
2. Principles of the Awaji-shima Consensus Recommendations 
The diagnosis of ALS requires 
 
A: evidence of lower motor neuron (LMN) loss (reduced interferential pattern on full contraction and 
increased firing rate) 
B: evidence of reinnervation (motor units of large amplitude and longer duration) 
C: fibrillation and sharp-waves OR fasciculation potentials (fibrillation and sharp-waves are required in 
weak limb muscles).  
 
3. Number of muscles affected by region 
Cervical and Lumbar-sacral region 
A minimum of two muscles innervated by different roots and nerves 
 
Bulbar and Thoracic region 
A minimum of one muscle  
 
 
 Clinical features 
 The first author to clearly recognize ALS as a clinico-pathological entity was the 
renowned French neurologist Jean Martin Charcot in 1869 (Charcot, 1869). 
 Roughly, two thirds of typical ALS patients present with a spinal form of the 
disease. The initials symptoms are typically focal muscular weakness of insidious onset, 
either proximally or distally in upper and/or lower limbs. Muscle wasting may precede 
focal weakness, and sometimes fasciculations or cramps may appear months before any 
weakness. These symptoms are usually asymmetrical (monomelic) at start, but  
eventually progress to the other limbs, and most patients go on developing bulbar and 
respiratory symptoms.  
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 Bulbar onset patients usually notice difficulty speaking clearly or swallowing, 
which eventually evolves to severe dysarthria or dysphagia. Limb symptoms eventually 
occur within some months of the first complaints. 
 A smaller proportion of patients (≈ 3%) present with respiratory weakness 
without significant limb or bulbar symptoms. 
 Clinically, all of these patients present some of the following symptoms or signs: 
 Focal muscle atrophy 
 Fasciculations 
 Spasticity 
 Pathologically brisk tendon reflexes 
 Hoffmann's sign 
 Babinski's sign 
 Dysarthria 
 Dysphagia 
 Fasciculations and wasting of the tongue 
 Respiratory failure and other pulmonary complications are usually the cause of 
death in ALS patients. 
  
 Epidemiology 
 The majority of ALS cases are sporadic. Only about 5-10% of cases have any 
kind of familiar history of ALS (Anderson, 2003). 
 The incidence of sporadic ALS is, in average, 1.9-2.1 per 100000/year in Europe 
and North America without significant differences between the different countries 
(Worms, 2001; Logroscino et al, 2010). A constant finding in studies is the higher 
number of men affected, with a M/F ratio of around 1.5:1 (Abhinav et al., 2007; 
Logroscino et al., 2008; Worms, 2001). 
 The mean age of onset for sporadic ALS varies between 55-65 years with a  
median age of onset of 64 years (Haverkamp et al., 1995; Leigh, 2007). Only around 
5% of cases have an onset before 30 years of age (Haverkamp et al., 1995), although 
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juvenile sporadic ALS cases are being progressively more recognized (Gouveia e de 
Carvalho, 2007). Bulbar onset is commoner in women and in older age groups of 
patients (Haverkamp et al. 1995). 
 Although the incidence of ALS is thought to be regionally uniform, there are 
some clusters in some regions in the Western Pacific where the prevalence may be 50-
100 times higher than elsewhere. The Guam island, the West Papua and the Kii 
peninsula in Japan are the three largest areas of increased incidence. These patients have 
ALS associated with Parkinsonism and Dementia (Armon 2003). Despite the decrease 
in incidence of ALS in these areas over the past 40 years, the cause of these clusters are 
still unveiled (Steele and McGeer, 2008; McGeer and Steele, 2011). 
  
 Etiology 
 The actual cause of ALS is still unidentified, despite some genetic risk factors 
have been acknowledged. At present time, most authors believe that a complex 
interaction between genetic and environmental aspects is the causal factor for motor 
neuron degeneration (Shaw, 2005) 
  
 Pathogenesis 
 The precise molecular pathway leading to degeneration of motor neurons in ALS 
is still unknown. But, taking as example other neurodegenerative disorders, most likely 
this will be an intricate interaction among multiple pathogenic cellular mechanisms. 
 Since the purpose of this work is not to review exhaustively ALS, we will only 
list some cellular mechanisms that have been shown to be deregulated in tissues of ALS 
patients: 
 Protein aggregation and endoplasmic reticulum stress 
Excitotoxicity 
Oxidative stress 
 Proteasome Inhibition and Autophagy 
 Mitochondrial dysfunction and Apoptosis 
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 Neuroinflammation 
 Impaired axonal transport 
 Deficits in neurotrophic factors and dysfunction of signalling pathways 
 Transcriptional dysfunction 
Genetic factors 
 
Histopathological features 
 Regarding pathologic features, the hallmarks in ALS include the degeneration 
and loss of motor neurons with astrocytic gliosis and the presence of intraneuronal 
inclusions in degenerating neurons and glia. 
 In the upper motor neurons, there is a depopulation of the Betz cells in the motor 
cortex, variable astrocytic gliosis, and axonal loss within the descending pyramidal 
motor pathway connected with myelin pallor and corticospinal tract gliosis. 
 In lower motor neuron pathology, there is degeneration of the ventral horns and 
brainstem motor neurons leading to the death of these cells. The remaining neurons are 
atrophic and may contain intraneuronal inclusions such as Ubiquitinated (TDP-43) 
inclusions (Neumann et al., 2006), Bunina bodies (Okamoto et al., 2008), and Hyaline 
conglomerates (Wood et al., 2003). 
  
Diagnosis and monitoring of disease progression 
 There are a variety of investigations that can help in the diagnosis of ALS either 
by documenting neurogenic or active denervation signs, or by excluding other 
conditions that can mimic ALS. 
 Electrophysiological studies 
 Electrophysiological studies are the most important investigation to rule out 
other mimicking conditions and to confirm the diagnosis of ALS. Neurogenic changes 
and/or signs of active denervation such as fibrillation potentials, positive sharp waves 
and fasciculations potentials have a fundamental role in the current criteria for ALS 
diagnosis (de Carvalho et al. 2008). 
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 Nerve conduction studies 
NCS allow the exclusion of peripheral nerve pathologies such as Multifocal 
motor neuropathy, that can mimic ALS presentation. These studies are generally normal 
or near normal, except for the amplitude of the compound muscle action potential that 
can be diminished (Brooks et al., 2000). 
 Conventional electromyography 
Needle EMG is the most selective tool for demonstrate signs of lower motor 
neuron dysfunction. It can identify widespread loss of motor units even before it is 
clinically detectable. 
Active denervation signs such as fibrillation potentials and positive sharp waves, 
and chronic denervation signs such as large motor unit potentials with increased 
duration, reduced interference pattern with higher firing rates and unstable motor unit 
potentials, are only demonstrable through needle EMG. 
Fasciculation potentials are a significant feature of ALS. Not only they have an 
upgraded value in the diagnosis (de Carvalho et al., 2008), but they can offer some 
understanding of the pathophysiology of ALS. 
Transcranial magnetic stimulation (TMS) 
TMS offers a non-invasive and reliable method of assessing upper motor neuron 
function. Changes in cortical motor threshold and cortical silent period can be 
documented with this technique and have shown to be correlated with disease 
progression (de Carvalho and Swash, 2010). 
Quantitative electromyography 
MUNE techniques are special neurophysiological methods that estimate the 
number of functional motor units on a giving muscle (Bromberg, 1993; Daube, 2006). 
The neurophysiological index is a mathematical derivation of three standardised 
neurophysiological measurements, representing aspects of the effects of denervation and 
reinnervation and of the excitability of anterior horn cells (Swash and de Carvalho, 
2004, Cheah et al., 2011). 
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These methods, while not perfect, are sensitive to quantify disease progression 
and have both been applied in clinical trials (de Carvalho and Swash, 2005; de Carvalho 
et al. 2005). 
Neuroimaging studies 
The main role of neuroimaging in ALS is to exclude structural lesions that may 
mimic ALS symptoms. 
Magnetic resonance imaging (MRI) may identify changes in the corticospinal 
tracts of ALS patients (Luis et al., 1990), but the role of this or other more advanced 
neuroimaging modalities in very limited in clinical practice. Nevertheless, there are 
recent studies regarding the use of neuroimaging in identifying potential biomarkers of 
disease progression (Turner et al., 2009) and in detection of changes before disease 
onset (Ng et al., 2008). 
 Clinical scales 
There are many clinical rating instruments to evaluate ALS patients that can 
assess disease status, follow progression and serve as endpoints in clinical trials. 
At the time, the commonly used and available instruments for the assessment of 
disease status and progression in ALS include the Norris scale (Norris et al., 1984), the 
Appel scale (Apple et al., 1987) and ALSFRS (ALS CNTF Treatment Study Phase I–II 
Group, 1996). 
The ALSFRS is a functional scale, proposed in 1996, designed to assess patients' 
abilities to carry out activities of daily living (ADL) grouped in  four categories: bulbar, 
upper extremity, lower extremity function and gross body function. Although this scale 
was demonstrated to be robust and reliable (Cedarbaum and Stambler, 1997) it granted 
disproportionate weighting to limb and bulbar, as compared to respiratory dysfunction 
(Cedarbaum et al. 1999). Therefore, the ALSFRS-R, which incorporates additional 
assessments of dyspnea, orthopnea, and the need for ventilatory support, was proposed 
three years later (Cedarbaum et al. 1999). 
  This scale is a sensitive and reliable score that has been largely used in 
clinical trials (Cedarbaum and Stambler, 1997) and has been proved to be predictive of 
survival (Kaufmann et al., 2005). 
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Management 
 ALS is considered an incurable disease, so treatment is mostly symptomatic. The 
majority of symptoms that arise during its natural course are treatable, and patients 
should be managed by a multidisciplinary team focusing on improving quality of life 
and patient's autonomy. Table 4 resumes the most common symptomatic treatments in 
ALS (Radunovic et al., 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4: Treatment of symptoms in ALS (Radunović et al., 2007) 
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 Nutritional management is of major significance in ALS. Since dysphagia is a 
common symptom, leading to increased risk of malnutrition, dehydration and weight 
loss, special care should be given to nutritional status. Eventually, enteral feeding most 
be considered, with percutaneous endoscopic gastrotosmy (PEG) being the standard of 
care (Leigh et al., 2003). PEG has been suggested to maintain a good nutritional status 
and prolong survival in ALS patients (Mazzini et al., 1995). 
 Weakness of respiratory muscles develops as the disease progresses and is a 
significant indicator of survival. It ultimately leads to respiratory complications, being 
the main cause of death in ALS (Gil et al., 2008). Erect forced vital capacity and vital 
capacity along with percutaneous nocturnal oximetry are the most commonly used tests 
to assess respiratory function. The latter can be useful to determine the need for non-
invasive positive-pressure ventilation (NIPPV) (Pinto et al., 2003). NIPPV has been 
shown to improve survival and quality of life (Pinto et al., 1995; Bourke et al., 2006) 
and is the preferred therapy to alleviate symptoms of respiratory insufficiency. 
 A vast number of clinical trials with various therapeutic targets have been 
reported in the literature. There are, currently, more than 150 trials registered with ALS 
as a target condition (http://clinicaltrials.gov). Despite this large number of studies, only 
riluzole has proven a modest effect on survivability (Bensimon et al., 1994; Lacomblez 
et al., 1996; Miller et al., 2007). One of the possible reasons for the lower success rate 
in ALS clinical trials may be the may be with the outcome measures chosen for these 
studies. Up until now, survival time and functional outcome have been chosen as the 
primary endpoints. Although these measures are of indisputable importance, they may 
be insensitive for screening new drugs (Costa et al., 2010). Consequently the need for 
sensitive biomarkers, like neurophysiological measurements or molecular biomarkers, is 
growing day by day. 
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 1.3 Motor unit number estimation 
 Ascertaining the number of axons innervating a specific muscle is of primordial 
importance in clinical neurophysiology. MUNE allows for a quantitative measure of the 
function of motor axons and it may be sensitive to mild degrees of axonal loss. Further 
than that, MUNE techniques are not influenced by the compensatory reinnervation 
process following denervation due to lower motor neuron degeneration, as opposed to 
motor amplitude. 
MUNE can provide significant information about the structure, organization and 
function of the brainstem and spinal cord motor system. Moreover, MUNE offers the 
chance to study the effects of age and muscle denervating diseases on motoneuron 
populations. It also can be used to establish the natural history of these disorders and to 
assess therapeutic efficacy of clinical interventions. 
Although theoretically MUNE allows various exciting possibilities, the lack of a 
standard anatomical determination of the number of motor units in a muscle has 
hampered the use and development of MUNE techniques. As previously mentioned in 
this work, anatomical studies of motor units are also, at best, estimates of the true 
number of motor units. 
The advent of physiological MUNE techniques happened in 1971 when 
McComas described his incremental stimulation method (McComas et al., 1971a). 
Despite being proposed over 40 years ago, the MUNE field was hindered during nearly 
20 years because of the initial application of the incremental stimulation technique in 
muscle diseases such as myotonic, Duchene or limbgirdle dystrophies (McComas et al., 
1971b; McComas et al., 1971c; Sica and McComas, 1971). Because much was yet to be 
learned regarding motor unit properties, the low values of MUNE recorded in these 
patients muscles were attributed to some type of dysfunction in their motoneurons. This 
hypothesis for the pathogenesis of muscle diseases was proven wrong, and the MUNE 
field lost the attention it deserved. 
In the next two decades, other techniques were described (Brown and Milner-
Brown, 1976; Lee et al., 1975; Brown et al., 1988; Stashuk et al., 1994; Daube, 1988, 
1995) but the crucial step was given in 1993 when Bromberg (Bromberg, 1993) studied 
the reliability of MUNE and considered its application for evaluating ALS patients. 
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These techniques will be explained in the next pages along with their advantages 
and limitations. 
Before we look at each individual method, we have to understand several basic 
assumptions about electrical characteristics that are made by MUNE techniques. 
All of these methods measure the average size (amplitude and/or area) of single 
motor unit potentials (SMUP), as well as the size (amplitude and/or area) of compound 
muscle action potential (CMAP) obtained by supra-maximal stimulation of a motor 
nerve. The MUNE is calculated by dividing the size of the maximal CMAP by the 
average size of the SMUP. These methods assume that each motor unit has a similar 
size and that it is the same size each time it is activated. It is preferable to use negative 
peak area or amplitude instead of peak-to-peak amplitude due to the effects of temporal 
dispersion in phase cancellation. If peak-to-peak amplitude is used, it may lead to an 
inflation of the average value and, consequently, to an underestimation of MUNE. 
What distinguishes these 5 techniques is the method used to obtain the SMUPs 
used to calculate the average SMUP. 
The first assumption is that the electrical activity recorded is derived from a 
single muscle. If a single motor unit potential is actually generated by a muscle at a 
distance from the recording electrodes its amplitude will be misleadingly small, leading 
to an overestimate of the motor unit number. For that reason, SMUPs with waveforms 
mostly positive in polarity, or with area<25 µV/ms or amplitude<10 µV are considered 
to arise from distant muscles and discarded (Bromberg, 2007). 
The second assumption is that the SMUP responses are, in fact, derived from a 
single motor unit. It is reasonable that two or more axons have similar thresholds 
causing a single response. This of course, can lead to erroneous MUNE values. As the 
number of stimulus increases though, this joint response will tend to decrease, giving 
different SMUP morphologies with each stimulus. This alternation phenomenon 
increases as the current stimulus increases due to higher probability of stimulating more 
and more axons. This is one of the reasons why is difficult to directly identify more than 
10 motor units in a muscle when stimulating a single point along the nerve. 
The third assumption is that a sample of 10 or 20 SMUP that are used to 
determine the average size of the SMUP are representative of the entire population of 
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SMUPs. Taking into account the classical studies regarding electrical stimulation of 
peripheral nerves (Erlanger and Gasser, 1937), we know that the largest fibers with 
higher conduction velocities have the lowest threshold. This can present a bias on the 
selection of the motor units used to calculate the average SMUP size. However, the 
clinical data reported in various studies using various techniques (McComas et al., 
1971; Doherty and Brown, 1993; Doherty et al., 1994) suggested that percutaneous 
electrical stimulation of motor axons provided an unbiased sample of SMUP. 
 
Incremental stimulation 
Incremental stimulation MUNE was the first physiological technique to be 
described (McComas et al., 1971). Despite its limitations, it was a major breakthrough 
in neurophysiology. 
It was applied to the extensor digitorum brevis (EDB), with a surface strip 
electrode placed so as to completely cover the end-plate zone of the muscle, and a 
reference electrode placed over the sole, considered to be an "inactive" spot. 
Consecutive, manually adjusted electrical stimuli (duration - 50 µsec; repetition 
rate - 0.25 Hz) were applied to the deep peroneal nerve at a site just above the ankle 
through a bipolar surface electrode (cathode distal to the anode). 
With progressive increases in stimulus intensity, incremental increases of the 
CMAP size were perceived. Each consecutive increment of the CMAP was considered 
to represent the addition of a SMUP as its threshold was reached. About 10 quantal 
increments were obtained in order to get a somewhat representative sample of SMUPs. 
 
 
 
 
 
Figure 3: Incremental stimulation 
MUNE (McComas et al., 1971a) 
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The average amplitude of SMUP was then calculated and maximal amplitude of 
the CMAP divided by it in order to estimate the number of motor units. 
This is a rather simple and elegant method that can be most effective when there 
is a reduction in the number of motor units in the studied muscle. In this case, the 
individual steps with stimulus current changes can be quite easily identified. On the 
contrary, in a young and healthy subject with a large number of motor units, the 
thresholds of motor axons quite often overlap, making quantal increments very difficult 
to identify. 
When the thresholds of two or more axons overlap at a given stimulus intensity a 
set of stimuli can evoke 2
n
-1 increments to the CMAP, where n is the number of axons 
with that threshold overlap. These steps (alternations) represent the possible 
arrangements of SMUPs, which in turn represent the variation, from stimulus to 
stimulus, of the motor units responding. This can lead to an underestimation of the 
SMUP size and, consequently, to an overestimation of the number of motor units. 
 
 
 
 
 
 
 
 
 
 
Another pitfall is the operator bias in the choice of the increments that actually 
represent an addition of a SMUP to the CMAP. 
 
Figure 4: Alternation phenomena in a series of 100 constant intensity stimuli 
(Doherty et al., 2003) 
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Multiple point stimulation 
In order to surpass the problem of alternation, stimulation of multiple points 
along the peripheral nerve path was suggested, originating the multiple point 
stimulation technique (Brown and Milner-Brown, 1976; Kadrie et al., 1976). These two 
first papers gave somewhat different results in obtaining a more representative SMUP 
sample and this method was not considered suitably for MUNE. However, these studies 
shed some light into the recruitment pattern of motor units. 
The modification introduced by Brown and Milner-Brown, was to stimulate the 
motor nerve in various (10 to 20) sites along the length of the nerve and record only the 
first all-or-nothing motor unit potential. The stimulus is given at 1 Hz with 50 to 100 µs 
duration with the cathode distal. Starting from a site just proximal to the motor point, 
the first single reproducible, all-or-nothing, free of alternation SMUP is found. After the 
first SMUP is found, the cathode is moved a short distance distally and the process is 
repeated until at least 10 SMUPs are recorded. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: SMUPs obtained by multiple point stimulation MUNE 
(Doherty et al., 1995) 
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This simple change in methodology avoided completely the problem of 
alternation and seemed to be a great advance in the MUNE field. Despite thse promising 
features, multiple point stimulation was left aside until 1993 when Doherty and Brown 
used this method to study the number and size of motor units in adults (Doherty and 
Brown, 1993). This technique was used by Felice in ALS patients and controls, in an 
elegant study that proved the utility of MUNE in the assessment of ALS (Felice, 1995). 
An adaptation of this technique was described by Wang (Wang and Delwaide, 
1995), which consists in recording only two or three clearly identifiable SMUPs in each 
point of stimulation in order to avoid alternation, and at the same time allowing for the 
increase of the SMUP sample. However, with this alternative method, there may be an 
increased probability of recruiting the same motor unit in different stimulation sites. 
Advantages 
The advantages of multiple point stimulation technique are: the average SMUP 
size is based on real motor units and not a statistical estimate or an estimate derived by 
algorithms intended to correct for alternation; there is no alternation; near motor 
thresholds stimuli are well tolerated by the subjects. 
Disadvantages 
The possibility of recording the same SMUP when stimulating at different sites 
along the nerve, is one of the most striking issues in multiple point stimulation MUNE. 
A formal method to detect duplicate SMUP is the collision technique, as described by 
Aoyagi (Aoyagi et al., 2000). However, collision studies are not viable in a clinical 
setting, so the primary means of identifying duplicate SMUPs is the comparison of 
waveforms signatures. Another drawback of this method is that in only applicable to 
distal muscles as it is required at least 50-100 mm of the motor nerve to allow collection 
of at least 10 SMUPs. 
 
F-Response method 
Following some studies on F-responses elicited by submaximal stimuli (Komori 
et al., 1991; Doherty et al., 1994) and the interpretation of these responses as a single 
motor unit potential, Stashuk and colleagues (Stashuk et al., 1994) proposed a method 
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of estimating the number of motor units based on the automated analysis of the F-
responses. 
This technique applies series of 200-300 successive submaximal stimuli (10-
50% of maximal CMAP) to a motor nerve at a rate of 2 Hz, recording 100 ms of surface 
EMG signal on a muscle innervated by that nerve. An F-response is considered to be 
representative of a discharge of a single motor unit, when 2 or more responses with 
identical shape, size and latency are recorded within the set of 200-300 stimuli. 
 
 
 
 
 
 
 
 
 
 
The recorded traces are then analyzed either automatically or manually in order 
to identify the SMUPs. The manual method can take up to 3h for scanning the entire set 
of responses, thus making it impractical in the clinical setting. An algorithm was then 
developed (Stashuk et al., 1994) in order to automatically select the F-responses 
considered being SMUPs. 
When a representative sample of SMUPs is collected (at least 10), the average 
size is calculated, and used to estimate the number of motor units by dividing the size of 
the CMAP by the size of the average SMUP. 
 
Figure 6: Superimposition of 300 CMAPs and related F-Waves, used for the 
calculation of F-Wave MUNE 
(Stashuk et al., 1994) 
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Advantages 
This technique is carried out with a minimum of operator intervention, reducing 
a possible operator bias in choosing SMUPs. The low intensity of the stimulus applied 
is well tolerated by the subject. 
Disadvantages 
The F-responses may be derived by the activation of more than one motor unit, 
leading to an overestimation of the average size of the SMUP. Alternation phenomena 
cannot be fully excluded despite the robustness of the algorithm. This method requires 
special software that may not be available in every EMG machine. Finally, in some 
pathological condition, such as ALS, the physiology of the F-responses may be altered 
(e.g. hiperexcitability of the anterior horn cells, reduced number of responses) leading to 
an increased difficulty in recording the SMUP sample. 
 
Spike-Triggered Averaging 
One of the first major studies with spike-triggered averaging technique was by 
Brown and colleagues who applied this method to the biceps brachii muscle in healthy 
subjects (Brown et al., 1988). 
This method involves recording electrical activity from two channels. Using 
voluntary isometric contraction, motor units are recorded in one of the channels with a 
combination of an amplitude window discriminator and a needle electrode, isolating one 
motor unit from the rest of the electrical activity. The motor unit spike is then used as a 
trigger to record  the surface SMUP time-locked with the chosen motor unit, extracting 
this signal from the asynchronous surface detected EMG activity. The surface 
recordings where then averaged (200 to 500 traces) until no further changes in the shape 
of the SMUP occurred. Filter settings were 500Hz-5KHz for the intramuscular 
recordings and 0.1Hz-2KHz for the surface recordings. 
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 10 SMUPs where recorded and used to calculate the average SMUP size. The 
maximal CMAP, obtained by supramaximal stimulation of the musculocutaneous nerve 
at or just distally to the posterior axillary fold, was divided by the average SMUP, 
giving the estimate of the number of motor units. 
Advantages 
This method does not suffer from alternation problems and it can be applied to 
most muscles, including proximal ones that are not accessible by other techniques. The 
use of intramuscular needle recordings may provide information regarding motor unit 
firing patterns, fiber density, jitter, blocking or other pathopysiological phenomena of 
reinnervation or instability of neuromuscular transmission. 
Figure 7: Spike-Triggered Averaging MUNE in Biceps brachii muscle 
(Brown et al., 1988) 
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Disadvantages 
This method can be very lengthy for collecting a representative sample of 
SMUPs. It is somewhat uncomfortable for the subject as intramuscular needles are not 
painless. It requires the collaboration of the subject, by maintaining a steady 
contraction. The measurements of the negative area of the SMUPs can be tough because 
of the difficulties in establishing the onset and baseline of the SMUPs. It involves 
special software. Finally, there may be a bias in the selection of the SMUPs towards low 
threshold motor units because of the physiological order of motor unit activation, giving 
lower values of SMUP size. 
 
Decomposition-Enhanced Spike-Triggered Averaging 
In order to overcome some of the problems with the Spike-triggered averaging 
method, an algorithm was developed for combining EMG signal decomposition with 
Spike-triggered averaging (Stashuk and Brown, 1994). 
The goal of this improvement is to analyze segments of 20 to 60 s of EMG 
signal during moderate isometric contraction and extract the motor units signal recorded 
from intramuscular needles. In this manner, the operator is not required to manually 
select each intramuscular motor unit potential as a trigger for the surface SMUP, 
decreasing the time needed for each assessment, and providing a larger sample of 
SMUPs, and at higher levels of contraction. 
The original algorithm used for this method was designed for use with 
concentric needle electrodes and during isometric constant or slowly changing force 
contractions. The EMG signal was first filtered by a first-order differential filter 
(McGill et al., 1985) in order to attenuate most of the distant volume conducted EMG 
signal. This enhances the detection of motor unit action potentials (MUAP). The 
following step is the application of a multipass clustering algorithm to the set of MUAP 
recorded in a 5 s interval corresponding with the maximal level of motor unit 
recruitment. This allows for the estimation of the number of MUAP trains in the 
composite signal and the computation of the prototypical MUAP shape for each train. 
The Spike-triggering averaging technique is then applied, in order to collect SMUP 
from the surface electrodes. 
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Advantages 
This method can greatly enhance the Spike-triggering averaging technique by 
increasing the number of SMUPs obtained from each intramuscular detection, reducing 
the time required for the collection of the entire set needed for MUNE calculation. It 
reduces the level of subject cooperation that is needed for the test. It allows for the study 
of higher threshold motor units, reducing the bias of the Spike-triggering averaging 
technique towards the selection of low threshold motor units. 
Disadvantages 
Regardless of how capable the decomposition algorithm may be, the complex 
interference pattern recorded by the surface electrode often makes it quite difficult to 
clearly identify SMUPs. This prevents the use of negative peak area, obliging the use of 
peak-to-peak or negative amplitude that may lead to an erroneous estimation of the 
number of motor units. Intramuscular needles are still used, causing some discomfort to 
the subjects. Finally, special software is required for these analyses, which may not be 
available in every EMG machine. 
 
Statistical method 
The first time the statistical MUNE technique was reported in the literature was 
in 1988 (Daube, 1988), but it was only in 1995 that Jasper Daube described formally is 
method (Daube, 1995). 
The statistical method relies on the know relation between the variance of 
multiple measures of step functions and the size of the individual steps when these steps 
have a Poisson distribution. In a pure Poisson distribution the measures decrease at 
higher values and the variance of these measurements is equal to the size of the 
individual components making up each measurement. 
In a set of 30 constant submaximal stimuli there will be variability in the CMAP 
response related to the inherent differences of thresholds of individual axons. Given that 
the differences on the CMAP follow a Poisson distribution, the variance of this 
distribution will correspond to the average size of the SMUP. 
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Firstly, a scan of 30 stimuli with increasing equal increments is done in order to 
identify unusually large steps in the CMAP. 
 
 
 
 
 
 
 
 
 
 
Figure 8: Series of motor responses to increasing stimuli, following a Poisson 
distribution 
(Daube et al., 1995) 
Figure 9: Normal (left) and abnormal (right) CMAP scanning curves 
(Daube et al., 1995) 
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If all steps on the scan are small, as it is in normal subjects, stimulus intensity 
eliciting response windows 10-20%, 25-35%, 40-50% and 55-65 % of maximal 
response are chosen, and 4 to 10 trials of 30 stimuli with that intensity are applied. The 
results of the different trials are then averaged, thus obtaining the estimation of number 
of motor units. 
On the other hand, in subjects with denervation and reinnervation such as ALS, 
if the CMAP scan detects true gaps (>10 % of total range), these gaps are attributed to a 
single SMUP, and a series of operational guidelines is needed in order to account for 
these large motor units (see Bromberg, 2007). 
There is still a large debate regarding technical details around this method. Not 
only the window size (5 or 10 %) and the placement of the windows along the scan 
curve are a matter of discussion, but there is no agreement in using Poisson or binomial 
distribution on the statistical method (Blok et al., 2005; Bromberg, 2007). 
Advantages 
It is a relative fast technique (around 15 minutes per muscle), without significant 
discomfort for the patient as it only uses submaximal electrical stimulation. It is 
applicable to almost every muscle where a CMAP is obtainable. Alternation is not a 
problem in this method. Also, as it uses a wide range of stimulus intensities, motor 
axons with different thresholds are recruited, thus providing with a representative 
sample of the SMUPs. 
Disadvantages 
There are a wide number of operator variables on this method. Up until today, 
there is a lack of a broad consensus on these variables and its implications on MUNE 
calculations. Special software is required for this technique, which is not available in 
every EMG machine. 
 
High density MUNE 
Van Dijk and collaborators proposed a new method of MUNE mixing elements 
from the Incremental stimulation and Multiple point stimulation techniques, with 120 
channel high-density surface electromyography (HD-EMG). This combination may 
MUNIX – A new method of motor unit number estimation 
Neurosciences Master, 2012  38 
resolve the problem of alternation to a large extent, allowing a collection of a larger 
SMUP sample, hence increasing the MUNE accuracy. 
The HD-EMG allows the decomposition of recorded submaximal CMAPs into 
the contributions of single motor units by adding spatial information to the obtained 
waveforms, thus distinguish individual SMUPs. 
Despite the advantage of increasing the SMUP sample, this method has several 
drawbacks. When the number of SMUPs contributing to a given submaximal CMAP is 
high (more then 4), the accuracy and reliability of the SMUPs detection decreases 
significantly. It requires special electrodes and software that may not be easily available. 
Finally, each assessment can take more than 60 minutes, making it not viable in a 
clinical setting. 
 
Bayesian statistical method 
One of the most intricate, yet promising, techniques recently proposed is the 
Bayesian approach to the statistical MUNE (Ridall et al., 2006; Henderson et al., 2007). 
This method uses data from the entire stimulus–response curve of a particular 
nerve collected by gradually increasing the stimulus intensity over at least 500 stimuli. 
 A Bayesian model is then applied to this data, as described by Ridall (Ridall et 
al., 2006) in order to obtain a probability that a certain number of motor units in that 
muscle is true. 
 The use of Bayesian statistics allow for the incorporation of a number of 
variables into the equation, avoiding the assumptions made by the Statistical method - 
the single MUAPs have the same size and that the units firing probabilistically, for a 
given stimulus, have the Poisson distribution. Instead, the Bayesian method incorporates 
probabilistic motor unit firing and motor unit size variability into the model. 
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This method also has some assumptions: 
 Motor units fire independently of each other in an all or nothing response and 
the response to each stimulus is independent of the response to previous stimuli. Motor 
unit firing only occurs if the stimulus intensity exceeds a variable threshold. The 
threshold for each unit is distributed as a Gaussian variable with its own mean threshold 
and precision parameter. The mean threshold is defined as the stimulus at which a unit 
has a 50% probability of firing. The precision parameter defines the range over which 
the unit exhibits probabilistic firing. The probability of a unit firing as a function of the 
stimulus can therefore be represented by a sigmoidal curve known as an “excitability 
curve” (Brown and Milner-Brown, 1976). 
 Each motor unit upon firing emits an action potential in the muscle characterized 
by an area or amplitude which is independent of the stimulus and normally distributed 
about a mean particular to that unit with a variance common to all units. (These means 
can then be allocated a suitable distribution to describe their between-unit variability.) 
 The measured CMAP area is the superposition of the muscle action potentials 
(described by Assumption2) of those units that respond to a stimulus (as described in 
Figure 10. Stimulus–response curves (left) and the calculated motor unit number and distribution of motor units (right) in a 
normal subject (top) and an ALS subject (bottom). In the posterior distribution the most likely number in the normal subject 
was 79 (71–89) and in the ALS subject 29 (25–34). 
Henderson et al., 2007 
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Assumption 1) together with a component from the baseline noise, which itself is 
normally distributed with its own mean and variance. 
Although this assumptions are well debated in the original paper (Ridall et al., 
2006), more studies are needed in order to verify if these are undisputable. Correlation 
of data obtained by this method with MUNE values calculated with other methods is 
also desired. 
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1.4 MUNIX 
MUNIX stands for "Motor unit number index" and it is a new method for 
estimating the number of motor units in a muscle. It was described in 2004 (Nandedkar 
et al., 2004), and it is being tested in a multicenter study, in which our laboratory is 
included, not only in control subjects (Neuwirth et al., 2011a; Neuwirth et al., 2011b), 
but also in ALS patients (Unpublished data). This method uses a mathematical model 
based on the CMAP and the surface EMG interference pattern (SIP) to derive an index 
related to the number of motor units, and not the actual number. However, in a previous 
study (Neuwirth et al., 2010) MUNIX values from the abductor pollicis brevis (APB) 
were correlated with previously published data using other MUNE techniques. 
This method is a three-step process. Firstly, the CMAP of the desired muscle is 
recorded by stimulating supramaximally the appropriate motor nerve with standard 
nerve conduction techniques. As MUNIX calculations relies on the CMAP amplitude 
and area, it is important to ensure that the maximum CMAP amplitude is recorded. Non 
optimal electrode placement can give low CMAP values and underestimate MUNIX. 
The negative phase of the CMAP is used to compute amplitude, area and power (the 
area and power are calculated by summating the absolute and square of the sample 
values, respectively, and multiplying it by the sampling interval for the measurement). 
The second step consists on the recording of the SIP, with each epoch containing 
300 ms of surface EMG signal. 
The patient is instructed to maintain an isometric contraction at 9 rising levels of 
force, starting on minimum and ending on full contraction. The force per se is not 
measured, as it would be impracticable, but the operator offers manual resistance to the 
patients movement, thus helping the recruitment of different levels of force. Each level 
of force will roughly correspond to 10% increments, from 10 to 100%, giving the 
patient a short rest before the maximal contraction. Either the CMAP and the SIP are 
recorded using a filter setting of 3-3000 Hz. 
The SIP epochs are analyzed in order to identify artifacts such as high frequency 
noise, power line frequency interference, baseline shift. Also tremor may occur, causing 
a nearly synchronous firing of motor units with high amplitude bursts. These situations 
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can lead to erroneous MUNIX calculations and recordings containing these artifacts 
should be rejected. 
There are some criteria for a SIP epoch to be accepted: 
 SIP area > 20 mV/ms 
 Ideal Case of Motor Unit Count < 100 
 SIP area / CMAP area > 1 
For the final step, all of the signals are imported to an independent analysis 
software for the MUNIX calculation. The mathematical model used for MUNIX 
computation is described next. 
 
MUNIX Mathematical model 
Let us assume an ideal case in a given muscle where all motor units are 
identical, with the same SMUP waveform, amplitude, area and power, where N= 
number of motor units; Mp= power of a single SMUP; and Mr= area of a single SMUP. 
Since the CMAP is the sum of all SMUPs, assuming there is no temporal dispersion, the 
CMAP waveform will be a magnified image of the SMUP. 
Giving these postulations, the CMAP area will be given by: 
𝐶𝑀𝐴𝑃 𝑎𝑟𝑒𝑎  𝐶𝑟 =  𝑁 𝑥 𝑀𝑟 
and the CMAP power will be (note that the power is proportional to the square): 
𝐶𝑀𝐴𝑃 𝑝𝑜𝑤𝑒𝑟  𝐶𝑝 =  𝑁 𝑥 𝑁 𝑥 𝑀𝑝 
Considering a slight voluntary contraction, when the subject activates few motor 
units, and assuming that the SMUPs do not superimpose, the SIP measurements will be 
given by: 
𝑆𝐼𝑃 𝑎𝑟𝑒𝑎  𝑆𝑎 =  𝐷 𝑥 𝑀𝑟 
𝑆𝐼𝑃 𝑝𝑜𝑤𝑒𝑟  𝑆𝑝 =  𝐷 𝑥 𝑀𝑝 
where D represents the number of SMUP discharges. 
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With some algebraic manipulation of the aforementioned relationships, one can 
easily verify that: 
𝑁 =  
𝐶𝑀𝐴𝑃 𝑃𝑜𝑤𝑒𝑟 𝑥 𝑆𝐼𝑃 𝐴𝑟𝑒𝑎
𝐶𝑀𝐴𝑃 𝐴𝑟𝑒𝑎 𝑥 𝑆𝐼𝑃 𝑃𝑜𝑤𝑒𝑟
 
This formula is called an Ideal case motor unit count (ICMUC) to reflect the 
ideal conditions used for its calculation. However, these assumptions can be reasonable 
met when the SIP is recorded at a low force contraction, with few motor units 
discharging at a low rate. 
When the force of contraction increases, larger motor units will be recruited and 
superimposition of SMUPs will also occur, giving higher amplitude signals. This will 
lead to a decrease in the ICMUC. So, to compare ICMUC values between subjects, 
standardization of force would be necessary. However, this can be a very laborious and 
tedious task, impracticable in the clinical setting. Instead, one can use the SIP area as 
reflection of force. 
A plot of the ICMUC vs. SIP area would reflect the number and size of the 
motor units recruited at the each force level. The following equation models the 
relationship between these variables in order to facilitate comparison and quantitation: 
𝐼𝐶𝑀𝑈𝐶 = 𝐴 𝑥 (𝑆𝐼𝑃 𝐴𝑟𝑒𝑎)𝛼  
The values of A and α are obtained through a linear regression between the 
recorded ICMUC and SIP area values. 
For the purpose of comparisons between laboratories, one as to define at what 
SIP area MUNIX calculation is made. The value of 20 mV/ms was then proposed by the 
authors (Nandedkar et al., 2004). Despite this value may seem a bit arbitrary, there are 
some practical reasons for it to be chosen. This SIP area is achieved with slight 
contraction, where the motor units recruited are small, with somewhat similar size and 
without significant superimposition, thus approaching as much as possible the ideal 
conditions of the model. If different SIP areas are used for the calculation, MUNIX 
values will differ, making it obvious that this computation is in fact an index and not a 
direct estimate of the number of motor units. 
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MUSIX 
A measure that can be easily obtained after the MUNIX calculations is the 
average size of a motor unit on the studied muscle. This value is called motor unit size 
index (MUSIX), is measured µV in and it is obtained according to the formula: 
𝑀𝑈𝑆𝐼𝑋 = 𝐶𝑀𝐴𝑃 𝐴𝑚𝑝𝑙𝑖𝑡𝑢𝑑𝑒 𝑀𝑈𝑁𝐼𝑋  
In contrast with most MUNE techniques that estimate the average size of the 
SMUP first and then the MUNE, this method calculates MUNE first and then SMUP 
average size. 
Advantages 
MUNIX is a non-invasive method that allows for a quick estimation of the 
number of motor units in a given muscle. In average only 5 minutes are needed for a 
muscle to be assessed. Also, it is not a very challenging method regarding technical 
difficulties. It is not discomfort for the subject as it only requires one CMAP to be 
obtained by electrical stimulation. It can be applied to any muscle, distal or proximal, 
where a CMAP can be obtained. Finally, it can be easily done in most EMG machines, 
since the software used to analyze the data is independent from the EMG software and 
can be executed in any computer. 
Disadvantages / Limitations 
For MUNIX measurements some degree of patient cooperation is required, 
which is not always achieved due to tremor , spasticity or cognitive dysfunction. The 
index given by this method is not an estimate of the true number of motor units, 
hindering the comparison with other MUNE techniques. 
When the motor units have a bimodal distribution it is not possible to achieve a 
full range of force levels. In this situation, the SIP will have low amplitudes at slight 
efforts and very large-amplitude at moderate and high efforts. This combination yields a 
higher MUNIX that would be expected for that muscle. When this bimodal distribution 
appears, changing the "SIP area > 20 mV/ms criteria" to 50 mV/ms will reduce 
significantly its influence on MUNIX calculations. 
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When the CMAP amplitude is very small the recording of SIPs can contain 
volume-conducted activity from nearby muscles (Nandedkar and Barkhaus, 2007). For 
this reason, when the CMAP in a muscle is < 0.5 mV, that muscle is considered not 
suitably for MUNIX measurements. 
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2. OBJECTIVES 
 
Primary: 
To assess the test-retest variability of a novel neurophysiological technique 
(MUNIX) for the estimation of the number of motor units in healthy subjects. 
 
 
Secondary: 
To evaluate the suitability of this technique as a potential marker of disease 
progression in ALS. 
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3. STUDY POPULATION 
 
The study population was be divided in two groups: a group of healthy subjects 
and a patient group (patients with ALS). 
 
Healthy subjects group 
This group comprised 15 healthy individuals older than 20 years without any 
medical or neurological disorders that might influence MUNIX measurements (e.g. 
peripheral nerve dysfunction, neuromuscular disorders, diabetes, oncological diseases or 
drug treatment with neurotoxic drugs). 
Informed consent was obtained from all subjects. 
The subjects were subdivided into two age groups, between 20 and 59 years and 
60 years or older in order to take into account the physiological loss of motoneurons 
associated with aging (Doherty et al., 1993). 
Patients group 
This group included patients with ALS/MND. These patients fulfilled the 
category for possible, probable lab-supported, probable or definite ALS regarding to the 
revised El Escorial criteria. All were diagnosed as ALS according to Awaji guidelines. 
The patients had a minimum follow-up of 9 months, with visits approximately every 3 
months. 
Symptom onset, defined as onset of weakness, muscle wasting, fasciculations, 
cramps (not present before), dysarthria, dysphagia, dyspnea, falls or disturbance of fine 
movements must be less than 18 months of baseline visit. 
Patients with any history of medical or neurological disorders that might 
influence MUNIX measurements (e.g. peripheral nerve dysfunction, neuromuscular 
disorders, diabetes, oncological diseases or drug treatment with neurotoxic drugs), were 
excluded. 
Informed consent was obtained from all subjects.  
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4. METHODS 
 
For the purpose of studying inter and intra rater variability, the healthy subjects 
group were evaluated twice by two separate investigators in an alternating fashion with 
a break of 30 minutes minimum between each assessment. Electrodes and marks were 
completely removed so that any traces of electrode placement were erased. This group 
was composed by 9 subjects with less than 60 years old, and 6 subjects with more than 
60 years old. The division into two age groups takes into account physiological loss of 
motoneurons at a higher age and that the onset of ALS peaks in the 6th decade (Doherty 
et al., 1993). 
In both ALS patients and healthy subjects, the following muscles were assessed: 
abductor pollicis brevis (APB), abductor digiti minimi (ADM), biceps brachii (BB), 
tibialis anterior (TA), abductor hallucis (AH) and extensor digitorum brevis (EDB) after 
supramaximal distal stimulation of the median, ulnar, musculocutaneus, tibial and 
peroneal nerves, respectively. In ALS patients the clinically less affected side was 
examined. If both sides were affected symmetrically, the right side was chosen. Since 
the loss of motoneurons is often focal in ALS, measurements in multiple muscles 
(proximal and distal; upper and lower limbs) will probably reflect the amount of 
functioning motor units more accurately. For that purpose, the MUNIX and CMAP 
megascores were calculated by aggregating the results of individual muscles in a 
subject. 
In ALS patients the following clinical data was collected: gender, age, region of 
onset and disease duration The ALSFRS-R scale (Cedarbaum et al. 1999) was applied 
at the time of MUNIX calculation. Before performing MUNIX measurement, manual 
muscle testing according to the Expanded Medical Research Council Scale for Manual 
Muscle Testing (MRC) was performed in each investigated muscle.  
ALS patients were evaluated approximately every 3 months (± 4 weeks) for a 
period of 9 to 12 months. Multiple point stimulation MUNE (Brown and Milner-Brown, 
1976; Kadrie et al., 1976) in ADM was also performed in every visit for the purpose of 
comparison between the two techniques. 
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The same surface electrodes (Cardinal Health, Madison, WI, USA, disposal 
ground and 2 disc electrodes, 15mm diameter, Ref 019-415200) were used throughout 
the study. Measurements were performed using a Keypoint® EMG machine. 
For the measurements, subjects were positioned in a comfortable, supine 
position. MUNIX measurements were performed according to the manner previously 
described in this work (see 1.4 MUNIX). 
Particular attention was paid to electrode placement and limb position, in order 
to ensure consistency between repeated measures. The tested muscle was fully relaxed 
and in neutral position. Skin surface was always cleaned properly before applying 
electrodes. Positioning of the stimulation and recording electrodes and distances 
between the active and reference electrode were standardized. 
Abductor pollicis brevis 
The active electrode was positioned in the thenar eminence; the reference 
electrode was positioned on the distal phalanx of the thumb; ground electrode was 
placed over the back of the hand. Electrical stimulation was applied on the median 
nerve just above the wrist, at 7 cm from the active electrode. 
Abductor digiti minimi 
The active electrode was positioned on the hypothenar muscle; the reference 
electrode was positioned on the distal phalanx of the 5
th
 finger; ground electrode was 
placed over the back of the hand. Electrical stimulation was applied on the ulnar nerve 
just above the wrist, at 7 cm from the active electrode. 
Biceps Brachii 
The active electrode was positioned on the middle of the long head of the BB; 
the reference electrode was positioned on the medial epicondyle; ground electrode was 
positioned on the interior surface of the arm. Electrical stimulation was applied on the 
musculocutaneous nerve in the axillary fold. 
Tibialis anterior 
The active electrode was positioned on the proximal middle third of TA; the 
reference electrode was positioned on the patella; ground electrode was positioned on 
MUNIX – A new method of motor unit number estimation 
Neurosciences Master, 2012  50 
the interior surface of the leg. Electrical stimulation was applied on the peroneal nerve, 
posterior to the head of the fibula. 
Abductor hallucis 
The active electrode was positioned over the middle portion of the abductor 
hallucis; the reference electrode was positioned on the first toe; ground electrode was 
positioned on the internal malleolus. Electrical stimulation was applied to the tibial 
nerve posterior to the internal malleolus. 
Extensor digitorum brevis 
The active electrode was positioned over the extensor digitorum brevis; the 
reference electrode was positioned on the 5
th
 toe; ground electrode was positioned on 
the dorsum of the foot. Electrical stimulation was applied to the peroneal nerve just 
above the ankle. 
The recording electrode position was always adjusted in order to achieve 
maximal amplitude with minimum rise time and a sharp negative takeoff of the CMAP. 
In reproducibility investigations (healthy subjects group) the amplitude of the CMAP 
was maximized in each occasion, without referring to previous values. In serial 
investigations (ALS group) the amplitude of the previous assessment was used as the 
target amplitude. If CMAP amplitude was less than 0.5 mV, this muscle was excluded. 
For the SIP recordings, the activation of each muscle was carefully assessed, in order to 
avoid the recruitment of neighboring muscles, in particular in weak ALS patients. 
Special attention was paid to temperature (always higher than 29 degrees on the dorsum 
of hands and 27 degrees on the dorsum of feet).  
All the electrophysiological tests (MUNIX, MUNE and CMAP) were performed 
by the author. 
 
Statistical analysis 
For statistical analysis of variability (intra and inter-rater test–retest reliability), a 
two-way random, single measure intraclass correlation coefficient (ICC) was calculated. 
The ICC represents the variability over measurements of every subject divided by the 
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total variability of all subjects. The reliability of the mixed effects model was verified 
routinely by inspecting the distribution of the residuals using quantile plots. No 
systematic deviation from normality was detected. Intra- and inter-rater variability were 
estimated from mixed effect models with subject, examiner or visit as crossed random 
effects without fixed effects. ICC is the percentage of the inter subject variability 
compared to the total variability. High ICC values near 1.0 indicate that the raters have 
measured similarly. 
For the analysis of progression of the studied variables over time in the ALS 
population, a Repeated measures ANOVA was applied. Repeated measures ANOVA 
compares the average score at multiple time periods for a single group of subjects, 
determining whether or not changed has occurred over time. 
Since these variables have different scales, there was a need to normalize the 
results in order to compare them. For that purpose, the value that was obtained at the 
initial assessment was considered 100% for that patient. Subsequent results, obtained in 
return visits, are expressed as a percentage of the baseline value. 
In order to quantify this progression, the Area under the disease progression 
curve (AUC) was calculated for each variable, according to the Trapezoid rule, using 
the program GraphPad Prism 5
®
. 
 
 
 
 
 
 
 
 
Figure 12: Trapezoid rule for AUC calculation 
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The AUC was then normalized, by comparison with an AUC of a normal, non-
progressive subject (always the same results on return visits), thus reflecting a 
progression rate of the disease.  
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5. RESULTS 
 
5.1 Healthy subjects group 
Our healthy subjects group was comprised by 15 individuals, 9 with less than 60 
years and 6 with more than 60 years. In the total cohort there were 7 male and 8 
females. The mean age was 45.2 ± 20.7 years (range 22-76; median age 31). In the 
group <60 there were 5 males and 4 females with a mean age of 30.4 ± 10. years (range 
22-57; median age 28). In the group >60 there were 2 males and 4 females with a mean 
age of 67.3 ± 6 years (range 61-76; median age 66.5). 
 
5.2 Descriptive analysis of the results in the Healthy subjects group 
In table 5 are listed the mean values and standard deviations of CMAP and 
MUNIX of all measurements (four measurements per muscle). 
 
Table 5: Mean values of MUNIX and CMAP in healthy subjects 
n = 15 Mean SD Range 
MUNIX APB 143.1 47.0 78-260 
MUNIX ADM 168.7 45.2 86-270 
MUNIX BB 150.1 65.3 58-299 
MUNIX TA 149.0 33.1 86-222 
MUNIX AH 215.1 127.0 37-521 
MUNIX EDB
a
 110.6 59.4 39-247 
MUNIX MEGASCORE
a
 811.7 209.5 560-1348 
CMAP APB 8.2 2.0 5-14.4 
CMAP ADM 10.9 1.8 7.7-15.4 
CMAP BB 6.4 2.8 2.3-13.6 
CMAP TA 7.2 1.4 3.9-10.2 
CMAP AH 14.2 7.1 4.5-31 
CMAP EDB
a
 7.1 3.4 3.1-15.5 
CMAP
a
 47.0 9.0 34.9-66.1 
a - EDB, CMAP MEGASCORE and MUNIX MEGASCORE: n = 8 subjects 
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In table 6 are listed the mean values and standard deviations of CMAP and 
MUNIX of all measurements (four measurements per muscle), in the youngest group. 
 
Table 6: Mean values of MUNIX and CMAP in youngest controls 
n = 9 Mean SD Range 
MUNIX APB 165.7 46.4 78-260 
MUNIX ADM 183.6 45.7 116-270 
MUNIX BB 177.9 67.5 79-299 
MUNIX TA 158.1 30.6 101-222 
MUNIX AH 280.5 125.9 83-521 
MUNIX EDB
a
 147.0 75.5 50-247 
MUNIX MEGASCORE
a 
 1094.6 161.2 917-1348 
CMAP APB 8.9 2.2 5.3-14.4 
CMAP ADM 11.7 1.8 8.4-15.4 
CMAP BB 7.4 2.9 3.2-13.6 
CMAP TA 7.8 1.1 5.9-10.2 
CMAP AH 18.0 6.6 5.9-31 
CMAP EDB
a
 9.5 4.8 3.4-15.5 
CMAP MEGASCORE
a 
 59.6 5.0 49.9-66.1 
a - EDB, CMAP MEGASCORE
 
and MUNIX MEGASCORE: n = 2 subjects 
  
In table 7 are listed the mean values and standard deviations of CMAP and 
MUNIX of all measurements (four measurements per muscle), in the group with  older 
patients. 
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Table 7: Mean values of MUNIX and CMAP in older controls 
n = 6 Mean SD Range 
MUNIX APB 109.2 19.6 82-157 
MUNIX ADM 146.5 34.8 86-223 
MUNIX BB 108.3 31.2 58-189 
MUNIX TA 135.3 32.5 86-196 
MUNIX AH 119.6 34.9 37-174 
MUNIX EDB 98.4 49.1 39-213 
MUNIX MEGASCORE
 a
 717.4 118.9 560-994 
CMAP APB 7.1 1.2 5-10.5 
CMAP ADM 9.6 1.0 7.7-12.3 
CMAP BB 4.8 1.6 2.3-8.4 
CMAP TA 6.4 1.3 3.9-8.5 
CMAP AH 8.5 2.4 4.5-12.6 
CMAP EDB 6.3 2.4 3.1-12.2 
CMAP MEGASCORE 42.8 5.3 34.9-53 
   
 
The MUNIX and CMAP mean values were all significantly lower in the group 
with the older subjects, as demonstrated by an independent sample t-test. EDB muscle 
and MUNIX and CMAP megascores were not assessed since the group with young 
subjects had 2 controls (8 measurements) only. 
Table 8: Comparison of MUNIX and CMAP values between both group of controls 
 
< 60 (n=9) > 60 (n=6) 
t df 
Sig. (2-
tailed) 
 
Mean SD Mean SD 
MUNIX APB 165.7 46.4 109.2 19.6 6.485 50.7 .000 
MUNIX ADM 183.6 45.7 146.5 34.8 3.377 58.0 .001 
MUNIX BB 177.9 67.5 108.3 31.2 5.384 52.7 .000 
MUNIX TA 158.1 30.6 135.3 32.5 2.753 58.0 .008 
MUNIX AH 280.5 125.9 119.6 34.9 7.170 41.3 .000 
CMAP APB 8.9 2.2 7.1 1.2 3.840 56.9 .000 
CMAP ADM 11.7 1.8 9.6 1 5.702 56.9 .000 
CMAP BB 7.4 2.9 4.8 1.6 4.503 56.8 .000 
CMAP TA 7.8 1.1 6.4 1.3 4.267 58.0 .000 
CMAP AH 18 6.6 8.5 2.4 7.908 47.8 .000 
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Since the CMAP has importance in the MUNIX calculations, a correlation 
between CMAP and MUNIX values is to be expected. This is demonstrated by a 
Spearman correlation, where we can see that CMAP and MUNIX are highly correlated 
in all muscles analyzed. 
 
Table 9: Correlation between MUNIX and CMAP 
n = 60 APB ADM BB TA AH EDBª Megascoresª 
cc 0.681 0.708 .974 .777 .907 .910 .950 
p .000 .000 .000 .000 .000 .000 .000 
a - EDB and Megascores: n = 32 
 
 
5.3 Variability analysis 
The first step was to analyze the ICC of the total variability (inter-rater and intra-
rater) of all four measurements per muscle.  
 
Table 10: Overall ICC values 
Muscle ICC 
MUNIX APB 0.701 
MUNIX ADM 0.677 
MUNIX BB 0.567 
MUNIX TA 0.618 
MUNIX AH 0.782 
MUNIX EDB 0.749 
MUNIX 0.740 
CMAP APB 0.627 
CMAP ADM 0.578 
CMAP BB 0.502 
CMAP TA 0.709 
CMAP AH 0.938 
CMAP EDB 0.851 
CMAP 0.855 
 
The muscles with higher ICC were the small muscles in the hand (APB and 
ADM) and the small muscles of the foot (AH and EDB). The ICC of the MUNIX 
megascore (MUNIX) and the CMAP megascore (CMAP), given by the sum of the 
measurements of all muscles in one assessment, is 0.740 and 0.855, respectively. 
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The ICC of the mean inter-rater variability are listed in table 11. 
 
Table 11: Inter-rater ICC values 
Muscle ICC 
MUNIX APB 0.689 
MUNIX ADM 0.652 
MUNIX BB 0.520 
MUNIX TA 0.666 
MUNIX AH 0.782 
MUNIX EDB 0.737 
MUNIX 0.673 
CMAP APB 0.636 
CMAP ADM 0.454 
CMAP BB 0.435 
CMAP TA 0.718 
CMAP AH 0.925 
CMAP EDB 0.891 
CMAP 0.853 
 
MUNIX measurements in all muscles, apart from biceps brachii, showed ICC 
values above 0.6, with AH muscle exhibiting the highest ICC (0.782). The ICC of the 
MUNIX megascore was 0.673 and the CMAP megascore 0.853. 
The ICC of the mean intra-rater variability are listed in table 12. 
 
Table 12: Intra-rater ICC values 
Muscle ICC 
MUNIX APB 0.709 
MUNIX ADM 0.796 
MUNIX BB 0.700 
MUNIX TA 0.568 
MUNIX AH 0.868 
MUNIX EDB 0.749 
MUNIX 0.827 
CMAP APB 0.613 
CMAP ADM 0.802 
CMAP BB 0.666 
CMAP TA 0.725 
CMAP AH 0.974 
CMAP EDB 0.839 
CMAP 0.890 
 
MUNIX measurements in all muscles, apart from tibialis anterior, showed ICC 
values above 0.7, with AH muscle exhibiting the highest ICC (0.868). The ICC of the 
MUNIX megascore was 0.827 and the CMAP megascore 0.890. 
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5.4 Clinical group - ALS patients 
Our clinical sample of ALS patients comprised 11 patients, 10 males and 1 
female, with mean age 66.45 ± 10.18 years (range 51-86; median age 63). The mean 
duration of symptoms at baseline assessment was 12.88 ± 4.59 months (range 5-18; 
median 13.6). Regarding the type of onset of the disease, 3 patients had bulbar onset 
and 8 patients had limb onset. 
 
The mean and standard deviation values, at baseline assessment, of the several 
variables studied, are reported in table 14. 
 
Table 14: Descriptive statistics of the studied variables at entry 
 
N Minimum Maximum Mean 
Std. 
Deviation 
Median 
MUNIX 
MEGASCORE 
11 207 737 494.4 156.7 390 
MUNE ADM 11 21 150 79.6 41.5 66 
CMAP 
MEGASCORE 
11 14.9 47.5 33.3 9.6 30.4 
ALSFRS 11 37 45 41.4 2.6 36 
MRC 11 124 160 149.8 11.3 143 
 
We compared the values of MUNIX and CMAP megascores of ALS subjects at 
baseline to the values of the control group with a t-test for independent samples. The 
values of ALS subjects were significantly lower than the control group. 
 
Table 13: Age and disease duration of the ALS population 
 
Onset 
Bulbar Limb 
N Mean 
Standard 
Deviation 
N Mean 
Standard 
Deviation 
Age 
3 
64.21 12.89 
8 
67.34 8.93 
Disease_duration 12.17 5.55 13.17 4.20 
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Before starting the analysis of these variables over the time, we looked for a 
correlation between them. Since all of them, each in its own way, can reflect disease 
status, a correlation between them should be expected. A Spearman's rho was used to 
assess these correlations. In fact, all of them showed a significant, positive and 
moderate to strong correlations between them. 
 
Table 16: Correlation between all studied variables 
 
MUNIX MUNE CMAP ALSFRS MRC 
MUNIX 
MEGASCORE 
Correlation Coefficient 1.000 .629 .897 .860 .608 
Sig. (2-tailed) . .000 .000 .000 .000 
MUNE ADM 
Correlation Coefficient .629 1.000 .696 .507 .746 
Sig. (2-tailed) .000 . .000 .000 .000 
CMAP 
MEGASCORE 
Correlation Coefficient .897 .696 1.000 .716 .659 
Sig. (2-tailed) .000 .000 . .000 .000 
ALSFRS 
Correlation Coefficient .860 .507 .716 1.000 .598 
Sig. (2-tailed) .000 .000 .000 . .000 
MRC 
Correlation Coefficient .608 .746 .659 .598 1.000 
Sig. (2-tailed) .000 .000 .000 .000 . 
 
  
Table 15: Comparison of MUNIX and CMAP megascores between ALS patients and 
controls 
 
Controls ALS subjects t df 
Sig. (2-
tailed) 
 
Mean SD Mean SD 
   
MUNIX MEGASCORE 811.7 209.5 494.4 156.7 4.586 41 .000 
CMAP MEGASCORE 47.0 9.0 33.3 9.6 4.266 41 .000 
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5.5 Analysis of progression 
Since ALS is a neurodegenerative disease, and the purpose of this work was to 
analyze the suitability of a new marker of disease progression, we assessed these 
patients for 9 or 12 months since baseline visit. The assessments were made 
approximately every 3 months (3.3 ± 0.5 months; range 2.3 - 4.4). 6 patients had 3 
follow-up visits and 5 patients had 4 follow-up assessments (9 and 12 months, 
respectively).  
We started by analyzing the progression of each variable with a Repeated 
measures ANOVA. The first thing is to assess the Sphericity of each group of variables. 
The Mauchly‟s test is one of the most used for this purpose. As we can see in table 17, 
only CMAP MEGASCORE and ALSFRS do not fulfill the sphericity assumption for an 
α = 0.05. 
 
Table 17: Mauchly’s test of Sphericity 
 
Mauchly's 
W 
Approx. 
Chi-
Square 
df Sig. 
Epsilon 
Greenhouse-
Geisser 
Huynh-
Feldt 
Lower-
bound 
MUNIX 
MEGASCORE  
.473 6.539 5 .260 .749 .976 .333 
MUNE ADM .811 1.831 5 .873 .869 1.000 .333 
CMAP 
MEGASCORE 
.246 12.240 5 .033 .541 .630 .333 
ALSFRS .204 13.851 5 .017 .563 .665 .333 
MRC .564 4.992 5 .419 .777 1.000 .333 
 
We then proceed to the Repeated measures ANOVA, using the Greenhouse-
Geisser correction factor when the sphericity assumption is violated. Since only 5 of the 
11 patients had 4 follow-up assessments, we only analyzed the data up to the 3
rd
 return 
visit (9 months). Table 18 resumes these results. 
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Table 18: Repeated measures ANOVA results for the studied variables 
 Type 
III Sum 
of 
Squares 
df 
Mean 
Square 
F Sig. 
Partial 
Eta 
Squared 
Noncent. 
Parameter 
Observed 
Power 
MUNIX 
MEGASCORE 
.957 3 .319 27.345 .000 .732 82.036 1.000 
MUNE ADM 1.459 3 .486 8.583 .000 .462 25.748 .987 
CMAP 
MEGASCORE
a
 
.725 1.622 .447 17.033 .000 .630 27.632 .996 
ALSFRS
a
 .330 1.689 .195 17.495 .000 .636 29.551 .997 
MRC .072 3 .024 15.149 .000 .602 45.446 1.000 
a - Analysis with Greenhouse-Geisser correction factor 
 
From this table we can conclude that all variables have significant differences 
between any two assessments. Looking at the graphic displayed in Figure 13, we can 
see that all variables decline over the time. Merging the Repeated measures ANOVA 
results with the data observed from the graphic, we can conclude that all variables 
decline with time in a significant way. 
The post-hoc tests for each variable that allow the identification of the 
significant differences in each pair of assessments can be found in the annexes (Annex 
A, tables 31-35). 
Knowing that all variables decline significantly with time, we wanted to see if 
there were significant differences in each assessment. For that purpose, we applied the 
Friedman test. The statistical analysis revealed significant differences between any two 
variables in all assessments (table 19) – 3 Months (𝜒𝐹 
2  4 = 14.036;  𝑝 = 0.005;  𝑁 =
11); 6 Months (𝜒𝐹 
2  4 = 13.567;  𝑝 = 0.006;  𝑁 = 11); 9 Months (𝜒𝐹 
2  4 =
14.312;  𝑝 = 0.004;  𝑁 = 11). 
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 Figure 13: Progression of the five studied variables. Values represented are mean ± 1 standard error of mean (SEM). 
p values on the right side are from repeated measures ANOVA for each variable from baseline to 9 months. (a - Analysis with Greenhouse-Geisser correction factor) 
p values on the bottom are from Friedman tests comparing all variables in each assessment. 
p < .001 
p < .001 
p < .001ª 
p < .001ª 
p < .001 
p = .005 p = .006 p = .004 Not accessed since there 
were only 5 patients 
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We then proceed to investigate which pairs had significant differences in each 
evaluation time. For that purpose, we applied the Wilcoxon test for each pair within an 
assessment. Since this analysis requires multiple comparisons, we only consider 
significant p values ≤ 0.01. The significant differences are listed in table 20. 
 
Table 20: Wilcoxon test results 
 
ALSFRS_3m 
-   
MUNIX_3m 
ALSFRS_3m 
-     
CMAP_3m 
MRC_6m     
-   
CMAP_6m 
ALSFRS_9m 
-   
MUNIX_9m 
MRC_9m    
- 
MUNIX_9m 
MRC_9m    
-   
CMAP_9m 
Z -2.852 -2.581 -2.58 -2.536 -2.934 -2.584 
Asymp. Sig.         
(2-tailed) 
0.004 0.01 0.01 0.011 0.003 0.01 
Exact Sig. (2-
tailed) 
0.002 0.006 0.007 0.009 0.001 0.007 
Exact Sig. (1-
tailed) 
0.001 0.003 0.003 0.004 0 0.003 
Point 
Probability 
0 0 0.001 0.002 0 0.001 
 
Again, adding these results to the data observed from the graphic, we can 
conclude that MUNIX MEGASCORE and CMAP MEGASCORE show significant 
lower values, thus more progression, than ALSFRS and MRC. 
Despite these first results have shown statistical significance, they do not 
quantify the progression over time. In order to do that, we calculated the normalized 
AUC of all variables, according to the trapezoid rule. Although some assumptions are 
made with this method, it is a suitable form of measure progression. After calculating 
Table 19: Friedman test results for each assessment 
 3 Months 6 Months 9 Months 
N 11 11 11 
Chi-square 14.036 13.567 14.312 
df 4 4 4 
Asymp. Sig. .007 .009 .006 
Exact Sig. .005 .006 .004 
Point Probability .000 .000 .000 
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the AUC for each variable (table 21), we compared them using the Friedman test 
(𝜒𝐹 
2  4 = 11.855;  𝑝 = 0.015;  𝑁 = 11). Figure 14 displays a graphic representing the 
mean ± 1 SEM of the normalized AUC of each variable. 
 
Table 21: Descriptive statistics of the variables AUC 
 
N Mean 
Std. 
Deviation 
Std. Error 
of Mean 
Median 
MUNIX 
MEGASCORE 
11 22,1 11,4 3,4 25,6 
MUNE ADM 11 21,3 26,9 8,1 9,8 
CMAP 
MEGASCORE 
11 18,4 12,3 3,7 14,6 
ALSFRS 11 10,8 5,3 1,6 10,8 
MRC 11 6,3 4,0 1,2 4,7 
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p = 0.015 
Figure 14: Graphic representation of each variable AUC distribution. Values represented are mean ± 1 standard error of 
mean (SEM). 
p value on the top is from the Friedman test comparing the AUC of all variables. 
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Given the significant result of the Friedman test, we went on to search which 
pairs had significant differences. We applied the Wilcoxon test to every pair of 
variables, considering only p values ≤ 0.01 as significant, since we were dealing with 
multiple comparisons. 
Table 22: Wilcoxon test results 
 
ALSFRS – MUNIX 
MEGASCORE 
MRC – MUNIX 
MEGASCORE 
MRC - CMAP 
MEGASCORE 
Z -2.667 -2.669 -2.49 
Asymp. Sig. (2-tailed) 0.008 0.008 0.013 
Exact Sig. (2-tailed) 0.005 0.005 0.01 
Exact Sig. (1-tailed) 0.002 0.002 0.005 
Point Probability 0.001 0.001 0.001 
 
MUNIX MEGASCORE had a significantly larger progression rate than 
ALSFRS and MRC, whereas CMAP MEGASCORE had only had a larger progression 
rate than MRC. 
 
Bulbar onset vs. Limb onset – an exploratory analysis. 
It is well known that patients may have different progression rates, according to 
the type of onset of the disease. Also, bulbar onset patients may go further without limb 
compromise, hindering the ability of these methods to measure disease progression. In 
order to see if these different methods show significant differences between limb onset 
patients and bulbar onset patients, we applied a Mann-Whitney test to the AUC of those 
variables.  
Table 23: Mann-Whitney test results 
 
MUNIX 
MEGASCORE 
MUNE ADM 
CMAP 
MEGASCORE 
ALSFRS MRC 
Mann-Whitney U 11.000 8.000 10.000 8.500 12.000 
Wilcoxon W 17.000 14.000 46.000 44.500 48.000 
Asymp. Sig. .838 .414 .683 .474 1.000 
Exact Sig. .921 .497 .776 .515 1.000 
Point Probability .073 .061 .073 .024 .079 
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p = 0.921 p = 0.497 p = 0.776 p = 0.515 p = 1 
Figure 15: Distribution of AUC of all variables, divided by type of onset. Values represented are mean ± 1 standard error of 
mean (SEM). 
p value on the bottom are from Mann-Whitney tests. 
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Although no statistically significant difference was found between bulbar onset 
and limb onset patients, for any of the variables, these results have to be seen as an 
exploratory analysis, since we had only 3 bulbar onset patients on this group. 
 
5.6 MUNIX progression in different muscles 
6 muscles have been chosen for calculating the MUNIX megascore, 3 from the 
upper limb and 3 from the lower limb, 2 distal and 1 proximal in each limb. The 
MUNIX absolute values from each muscle at baseline are reported in table 24.  
 
Table 24: Descriptive statistics of MUNIX for each muscle 
 
N Mean 
Std. 
Deviation 
Median Minimum Maximum 
APB 11 74.2 41.3 74 23 171 
ADM 11 96.5 55.6 111 32 215 
BB 11 102.8 39.1 98 40 162 
TA 11 78.5 35.7 78 20 135 
AH 11 99.3 55.6 105 11 193 
EDB 11 43 28.3 47 5 82 
 
We went on to see if there were significant differences between these muscles in 
MUNIX measurements. 
The first step was to see if all muscles progress significantly with time. For that 
purpose we applied a Repeated measures ANOVA. The Mauchly‟s test (table 25) 
showed that only AH muscle did not fulfill the sphericity assumption. 
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Table 25: Mauchly’s test of Sphericity 
 
Mauchly's 
W 
Approx. 
Chi-
Square 
df Sig. 
Epsilon 
Greenhouse-
Geisser 
Huynh-
Feldt 
Lower-
bound 
APB .403 7.929 5 .162 .706 .900 .333 
ADM .535 5.457 5 .365 .761 .998 .333 
BB 0.541 5.362 5 .376 0.745 0.969 0.333 
TA .505 5.955 5 .313 .717 .919 .333 
AH .233 12.713 5 .027 .608 .737 .333 
EDB 0.739 2.634 5 .757 0.848 1 0.333 
 
We proceeded to the Repeated measures ANOVA, using the Greenhouse-
Geisser correction factor when the sphericity assumption is violated. Because only 5 of 
the 11 patients had 4 follow-up assessments, we only analyzed the data up to the 3
rd
 
return visit. Table 26 resumes these results. 
 
Table 26: Repeated measures ANOVA results for all muscles 
 
Type III 
Sum of 
Squares 
df 
Mean 
Square 
F Sig. 
Partial 
Eta 
Squared 
Noncent. 
Parameter 
Observed 
Power 
APB 1.659 3 .553 7.016 .001 .412 21.049 .963 
ADM 1.825 3 .608 17.133 .000 .631 51.398 1.000 
BB .712 3 .237 8.930 .000 .472 26.790 .990 
TA .817 3 .272 6.080 .002 .378 18.239 .934 
AHª 0.539 1.825 0.295 1.842 0.189 0.156 3.362 0.321 
EDB 1.066 3 .355 3.287 .034 .247 9.861 .692 
a - Analysis with Greenhouse-Geisser correction factor 
 
From this table we can conclude that all muscles, except AH, have significant 
differences between any two assessments. Looking at the graphic displayed in Figure 
16, we can see that all muscles decline with time. Adding the Repeated measures 
ANOVA results with the data observed from the graphic, we can conclude that all 
muscles, except AH, decline with time in a significant way. 
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The post-hoc tests for each muscle that allow the identification of the significant 
differences in each pair of assessments can be found in the annexes (Annex A, tables 
36-40). 
Knowing that all muscles decline significantly with time, we looked for 
significant differences in each assessment. We applied a Friedman test for this purpose. 
The statistical analysis revealed no significant differences between any two muscles in 
any assessment (table 27) – 3 Months (𝜒𝐹 
2  5 = 8.992;  𝑝 = 0.109; 𝑁 = 11); 6 Months 
(𝜒𝐹 
2  5 = 7.130;  𝑝 = 0.211;  𝑁 = 11); 9 Months (𝜒𝐹 
2  5 = 3.887;  𝑝 = 0.566;  𝑁 =
11). 
 
Table 27: Friedman test results for each assessment 
 3 Months 6 Months 9 Months 
N 11 11 11 
Chi-square 8.992 7.130 3.887 
df 5 5 5 
Asymp. Sig. .109 .211 .566 
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p < .001 
p = .000 
p < .000 
p < .002 
p < .034 
p = .109 p = .211 p = .566 
p < .189ª 
Figure 16: Progression of the studied muscles. Values represented are mean ± 1 standard error of mean (SEM). 
p values on the right side are from repeated measures ANOVA for each muscle from baseline to 9 months. (a - Analysis with Greenhouse-Geisser correction factor) 
p values on the bottom are from Friedman tests comparing all variables in each assessment. 
Not accessed since there 
were only 5 patients 
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We also quantified the progression of each muscle by calculating their respective 
AUC. After this calculation, we compared them using the Friedman test (𝜒𝐹 
2  5 =
5.237;  𝑝 = 0.388;  𝑁 = 11). Figure 17 displays a graphic representing the mean ± 1 
SEM of the AUC of each variable. 
 
Table 28: Descriptive statistics of the muscles AUC 
 
N Mean 
Std. 
Deviation 
Std. Error 
of Mean 
Median 
APB 11 21.4 23.1 6.9 21.3 
ADM 11 33.2 20.0 6.0 30.8 
BB 11 18.3 19.0 5.7 17.3 
TA 11 14.8 27.1 8.2 15.7 
AH 11 19.1 37.8 11.4 13.3 
EDB 11 22.8 40.6 12.2 21.7 
 
 
 
 
 
 
 
 
 
 
 
 
p = 0.388 
Figure 17: Graphic representation of each muscle AUC distribution. Values represented 
are mean ± 1 standard error of mean (SEM). 
p value on the top is from the Friedman test comparing the AUC of all muscles. 
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Although no significant differences have been found between the progression 
rates of the 6 studied muscles, we can notice that MUNIX in ADM muscle seems to 
have a slightly higher progression rate than other muscles. 
 
5.7 MUNIX vs. MUNE in ADM muscle 
An interesting analysis that we could do was to compare different techniques of 
motor unit number estimation. We compared the MUNIX to Multiple point stimulation 
MUNE in the ADM muscle. Figure 18 displays a graphic representation of the 
progression of these two variables with time. 
The repeated measures ANOVA for these variables has been previously 
calculated: MUNIX ADM (𝐹(3,30) = 17.133; 𝑝 < 0.001; 𝑂𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑝𝑜𝑤𝑒𝑟 =
1.000); MUNE ADM (𝐹(3,30) = 8.583; 𝑝 < 0.001; 𝑂𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑝𝑜𝑤𝑒𝑟 = 0.987) 
We applied a Wilcoxon test to look for significant differences in each 
assessment (table 29). 
 
Table 29: Wilcoxon test results 
 3 Months 6 Months 9 Months 
Z -1.718 -1.224 -1.734 
Asymp. Sig. (2-tailed) .086 .221 .083 
Exact Sig. (2-tailed) .098 .240 .090 
Exact Sig. (1-tailed) .049 .120 .045 
Point Probability .012 .008 .006 
 
No statistical significant difference has been found between MUNIX and MUNE 
in each assessment. 
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p = .098 p = .240 p = .090 
p < .001 
p < .001
  
Figure 18: Progression of MUNIX and MUNE in the ADM muscle. Values represented are mean ± 1 standard error of mean (SEM). 
p values on the right side are from repeated measures ANOVA for each method from baseline to 9 months. 
p values on the bottom are from Wilcoxon test comparing the two methods. 
Not accessed since there 
were only 5 patients 
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Despite no significant differences between MUNE and MUNIX in any 
assessment, when we look at the graphic we can notice that MUNIX has a steepest and 
linear decline than MUNE. Given that, we went to compare the AUC of the two 
techniques (table 30; Figure 19). 
 
Table 30: Descriptive statistics of ADM MUNIX and MUNE AUC 
 
N Mean 
Std. 
Deviation 
Std. Error 
of Mean 
Median 
MUNIX 11 33.2 20.0 6.0 30.8 
MUNE 11 21.3 26.9 8.1 9.8 
 
 
 
 
 
 
 
 
 
 
 
 
We applied a Wilcoxon test to compare the two methods (𝑆 += 4.5; 𝑆 −=
6.33; 𝑍 = −2.135; 𝑝 = 0.030; 𝑁 = 11). This test showed a significant difference 
between the two variables, with MUNIX having a higher progression rate than MUNE 
in the ADM muscle.  
p = .030 
Figure 19: Graphic representation of each method AUC distribution. Values represented 
are mean ± 1 standard error of mean (SEM). 
p value on the top is from the Wicoxon test comparing the AUC of the two methods. 
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6. DISCUSSION 
 
The objectives of this study were to evaluate the intra- and inter-rater reliability 
of MUNIX, a new method of MUNE described in 2004 (Nandedkar et al., 2004), as 
well as its suitability as a biomarker of disease progression in ALS patients. The 
technique is quick to perform (20 to 30 minutes for the 6 muscles), non-invasive and 
overall well tolerated by healthy volunteers and ALS patients. When compared to other 
well established MUNE techniques, MUNIX has some obvious advantages has it 
studies more muscles in the same time frame, requiring less electrical stimuli 
(Bromberg, 2007). 
Part of this work is included on a multicentre study designed to assess MUNIX 
reproducibility, from which some papers have already been published (Neuwirth et al., 
2011; Neuwirth et al., 2011a). 
 
6.1 MUNIX absolute values 
In normal subjects the absolute values of MUNIX were in line with the few 
studies published to date (Nandedkar et al., 2004; Ahn et al., 2010; Nandedkar et al., 
2010; Neuwirth et al., 2011; Neuwirth et al., 2011a), giving the first indication of the 
reproducibility of the method across centers. 
The comparison of the values obtained by the MUNIX method with values 
reported using other MUNE techniques (Daube 1988; Doherty and Brown, 1993; Wang 
and Delwaide, 1995; Shefner, 2004; Boe, 2007; Boe 2009), showed a high agreement 
for some of the muscles, indicating that MUNIX is at least as good as other techniques 
for the estimation of the number of motor units. 
In ALS patients, MUNIX values at baseline were, as expected, significantly 
lower than controls, reflecting the loss of motoneurons at the time of diagnosis (Swash 
and Ingram, 1988). Comparison of these values with other MUNIX studies in ALS 
patients is somewhat difficult given the differences in disease duration or type of onset. 
Of the few studies with this method, the majority of them only study the hypothenar 
muscle (Nandedkar et al., 2004; Ahn et al., 2010; Nandedkar et al., 2010), one studies 
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hypothenar and thenar muscle (Nandedkar et al., 2011) and one reports the MUNIX 
megascore from 8 muscles – APB, ADM, AH and EDB bilaterally (Neuwirth et al., 
2010). Regardless, the baseline values from our work in ALS patients are similar to the 
ones reported in the aforementioned studies. 
We should emphasize that MUNIX is an index related to the number of 
functioning motoneurons that might change depending on the parameters chosen, such 
as the area selected for the MUNIX calculation. Taking this into account, the 
comparison of MUNIX values with other techniques as to be taken cautiously. 
 
6.2 Variability analysis 
All muscles assessed showed a reasonably good ICC. There are no defined 
values for a bad/weak or good/strong ICC, only that the closest to 1, the highest the 
correlation. Its interpretation depends on the situation in analysis. In our particular case, 
taking into account that there was no previously experience with this method, the ICC 
values obtained can be considered rather good. It is expected that with training in the 
technique, these values can improve further. 
The muscles that showed the lowest test-retest-reliability were the BB and the 
TA. Since MUNIX depends highly on CMAP amplitude, it is expected that higher 
variability in CMAP measurements influence negatively the MUNIX reproducibility. 
The CMAP amplitude is highly dependent of the position of the active electrode 
(Bromberg and Spiegelberg, 1997), achieving the maximal response over the motor 
point of the muscle. In large muscles such as BB and TA, this can present a significant 
challenge. This difficulty in obtaining a maximal CMAP can lead to a higher variability 
in CMAP responses thus hindering the reproducibility of MUNIX. 
Another possible explanation for these lower reproducibility values is the 
increased difficulty in discerning levels of force in the contraction of larger muscles. In 
larger muscles, where fine motor control in unnecessary, a given motoneuron can 
supply more than 200 muscle fibers, making it difficult to distinguish slight increments 
on the contraction force. This can lead to erroneous SIP measurements, which in turn 
can hamper the reproducibility of the method in these muscles. 
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Our test-retest-reliability results are in line with other studies on MUNIX 
reproducibility (Nandedkar et al., 2004; Ahn et al., 2010; Nandedkar et al., 2010; 
Neuwirth et al., 2010; Neuwirth et al., 2011;). 
 
6.3 Progression analysis 
In ALS patients, MUNIX megascore had a progression of 22,1% from baseline 
to 9/12 months. MUNIX megascore showed a significantly higher relative drop from 
baseline than ALSFRS-R and MRC. Regarding CMAP and ADM MUNE, MUNIX 
showed a higher relative drop, although without statistical significance. Of note is that 
MUNIX showed a lower standard deviation than CMAP and ADM MUNE, as well as a 
steepest and steadier decline. 
A recent work with MUNIX method (Boekestein et al., 2012), also found 
significant higher decline of MUNIX in APB, comparing with ALSFRS and MRC. This 
study also reported a significant difference between MUNIX and CMAP, which we did 
not found. 
ALSFRS-R has been used as a primary or secondary outcome measure in ALS 
clinical trials (Shefner et al., 2004; Scelsa et al., 2005), has high reproducibility and 
linearity (Kaufmann et al., 2007) and it is easily applicable in non-specialized centers. 
Nevertheless, a marker of disease progression should track the underlying pathology of 
the disease besides being a functional measure. 
MRC has also been used a primary outcome measure in ALS clinical trials 
(Miller et al., 2001; Cudkowicz et al., 2003). However, MRC may lack the sensitivity 
needed to detect small but meaningful changes in deterioration and therapeutic efficacy. 
CMAP also has been previously used as an outcome measure in clinical trials 
(Brooke et al., 1986; Kaji et al., 1998). Still, CMAP may not succeed in detecting motor 
unit loss due to successful collateral reinnervation, thus failing to understand the 
potential effect of a tested drug in a clinical trial. 
Several MUNE techniques have been studied in ALS clinical trials (Shefner et 
al., 2004; Shefner et al., 2007; Bromberg and Brownell, 2008). However, we are still 
not sure if MUNE methods are equivalent or even better markers than other established 
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measures like ALSFR-R or forced vital capacity. Moreover, the value of MUNE 
techniques as a sensitive drug point for ALS drug studies has not been fully established 
(Bromberg, 2007), since it lacks the ability to predict clinical outcome (Bryan, 2003). 
About two thirds of ALS patients present with limb onset and the remaining with 
bulbar onset (Wijesekera and Leigh, 2009). Depending on the type of onset, the clinical 
features of ALS progression varies, with bulbar onset patients developing limb 
weakness later than limb onset patients. MUNE techniques are not usually applied in 
bulbar muscles, and MUNIX in this study also was not. This may lead to an 
underestimation of disease progression in bulbar ALS patients. In our preliminary 
analysis, MUNIX did not show differences in assessing disease progression in bulbar 
and limb onset patients, suggesting that it is a suitably technique independently of the 
disease onset type. However, more research is needed on this subject, since we had only 
three bulbar onset patients, thus limiting the conclusions that can be drawn. 
Given these considerations and the performance of MUNIX in this study, this 
novel method for estimating the number of motor units shows a high potential for a 
future role as a surrogate marker of disease progression in ALS clinical trials. 
 
6.4 Comparison of MUNIX progression in individual muscles 
Since ALS patients may present with a variety of clinical presentation, starting 
with focal weakness in upper or lower limb or bulbar muscles and then spreading to 
other areas (Ravits and La Spada, 2009), we opted to study several muscles, instead of 
one “index” muscle. However, the choice of the muscles included has to be carefully 
weighted. 
Due to its intrinsic technical characteristics, MUNIX offers the possibility of 
studying virtually every muscle where a maximal CMAP by electrical stimulation can 
be obtained. In this study we included six muscles, three for upper limb and three from 
lower limb, one proximal and two distal in each member. 
Our analysis showed that only AH did not progress significantly with time in 
ALS patients. The most likely explanation for this is that the electrical activity either in 
CMAP or SIP recordings is not only generated by the AH muscle, but also by volume-
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conducted activity from other muscles innervated by the tibial nerve (Nandedkar and 
Barkhaus, 2007). Also, from our experience, in AH muscle there is a particular 
difficulty in controlling the force of contraction for SIP recordings. This is special true 
in patients with lower motor unit numbers. This may lead to increased difficulty in 
complying with the technique specifications, thus hindering the method‟s ability to 
detect disease progression in this muscle. 
There were no significant differences in the rate of progression between all 
muscles, suggesting that MUNIX can be applied in a wide variety of muscles. 
Despite these results, the ADM muscles showed a slightly increased rate of 
progression, in comparison to the other five muscles, with a steepest and steadier 
decline, suggesting that it can be useful in settings where only one muscle is chosen, or 
for the comparison with other MUNE techniques. 
 
6.5 MUNIX vs. MUNE in ADM muscle 
This is the first study to compare MUNIX to another widely used MUNE 
technique (Multiple point stimulation MUNE). There was a significant correlation 
between MUNIX and MUNE in ALS patients at the baseline assessment. The two 
methods declined significantly with time, with MUNIX showing less variability than 
MUNE. In our results, MUNIX had a significantly lager rate of progression (33,2% vs. 
21,3%; p = 0,30) than MUNE. 
MUNIX does not rely on a calculation of the mean SMUP, as the majority of 
MUNE techniques (Bromberg, 2007), thus surpassing some of the physiological 
limitations intrinsic of these methods. Our results suggest that this may be a more 
suitably method to monitor disease progression in ALS patients than multiple point 
stimulation MUNE.  
A recent study comparing MUNIX to High-density MUNE in the thenar muscle 
(Boekestein et al., 2012) did not find any difference in the progression rate of these two 
methods. However HD-MUNE requires specific software and adapted electrodes for the 
high-density surface EMG that may not be easily available. Also, the detection of 
SMUPs in this method is very time consuming, thus limiting its use in clinical practice. 
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In the future it would be interesting to compare the progression of MUNIX with 
other MUNE techniques, such as the statistical MUNE, to observe if our results are 
replicated with other methods.  
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7. CONCLUSIONS AND STUDY LIMITATIONS 
 
Our work has achieved the objectives that we proposed. MUNIX seems to have 
a good test-retest-reliability in healthy subjects thus stressing its applicability in clinical 
practice. Regarding the method suitability to monitor disease progression in ALS 
patients, MUNIX has performed as well or even better than current used methods, such 
as ALSFRS-R, multiple point stimulation MUNE, CMAP or MRC. 
 
Throughout our work we encountered several problems and limitations. 
The first and more important limitation is the reduced number of ALS patients 
included in this work. Eleven patients is not at all an unacceptable number, particularly 
in a work with a novel method, but it is not enough to draw solid conclusions. Another 
important drawback is the follow-up time used in this study. All patients had nine 
months of follow-up, and only five had one year. Although some conclusions can be 
taken, as we demonstrated throughout this work, a longer follow-up time would be 
desirable in order to study the late phases of disease progression in ALS. 
Although, ALS is characterized by rapid clinical progression, and many of our 
patients could not be further investigated due to severe weakness, the previously 
mentioned problems could be approached by including more patients. Unfortunately, 
deadlines were imposed for the delivery of this work. 
Another question that was not addressed in this study was the test-retest-
reliability in ALS patients. Although this was in important point in studying MUNIX 
suitability, we did not had the opportunity to study each patient twice. 
 
Overall, our results support MUNIX as probably the most convenient and 
effective MUNE method to investigate progression in ALS. However, its limitation in 
very spastic limbs and in patient with poor cognitive function deserve further 
consideration in future studies. 
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ATTACHMENT A 
 
Table 31: Post hoc test comparing MUNIX MEGASCORE in each assessment 
(I) MUNIX 
MEGASCORE 
(J) MUNIX 
MEGASCORE 
Mean 
Difference 
(I-J) 
Std. 
Error 
Sig.ª 
95% Confidence 
Interval for 
Differenceª 
Lower 
Bound 
Upper 
Bound 
Baseline 
3 Months ,153 ,032 ,005 ,047 ,258 
6 Months ,265 ,057 ,006 ,077 ,452 
9 Months ,402 ,054 ,000 ,225 ,578 
3 Months 
Baseline -,153 ,032 ,005 -,258 -,047 
6 Months ,112 ,039 ,096 -,015 ,238 
9 Months ,249 ,043 ,001 ,107 ,392 
6 Months 
Baseline -,265 ,057 ,006 -,452 -,077 
3 Months -,112 ,039 ,096 -,238 ,015 
9 Months ,137 ,046 ,086 -,015 ,289 
9 Months 
Baseline -,402 ,054 ,000 -,578 -,225 
3 Months -,249 ,043 ,001 -,392 -,107 
6 Months -,137 ,046 ,086 -,289 ,015 
a - Adjustment for multiple comparison: Bonferroni 
 
 
Table 32: Post hoc test comparing MUNE ADM in each assessment 
(I) MUNE 
ADM 
J) MUNE 
ADM 
 
Mean 
Difference 
(I-J) 
 
Std. 
Error 
 
Sig.ª 
 
95% Confidence 
Interval for 
Differenceª 
Lower 
Bound 
Upper 
Bound 
Baseline 
3 Months ,053 ,110 1,000 -,307 ,412 
6 Months ,369 ,102 ,028 ,036 ,703 
9 Months ,406 ,124 ,049 ,001 ,812 
3 Months 
Baseline -,053 ,110 1,000 -,412 ,307 
6 Months ,316 ,085 ,024 ,038 ,595 
9 Months ,354 ,094 ,023 ,045 ,662 
6 Months 
Baseline -,369 ,102 ,028 -,703 -,036 
3 Months -,316 ,085 ,024 -,595 -,038 
9 Months ,037 ,090 1,000 -,256 ,331 
9 Months 
Baseline -,406 ,124 ,049 -,812 -,001 
3 Months -,354 ,094 ,023 -,662 -,045 
6 Months -,037 ,090 1,000 -,331 ,256 
a - Adjustment for multiple comparison: Bonferroni 
 
 
Table 33: Post hoc test comparing CMAP MEGASCORE in each assessment 
(I) CMAP 
MEGASCORE 
(J) CMAP 
MEGASCORE 
Mean 
Difference 
(I-J) 
 
Std. 
Error 
 
Sig.ª 
 
95% Confidence 
Interval for 
Differenceª 
Lower 
Bound 
Upper 
Bound 
Baseline 
 
3 Months ,123 ,028 ,009 ,030 ,215 
6 Months ,244 ,044 ,002 ,099 ,388 
9 Months ,342 ,073 ,005 ,101 ,583 
3 Months 
 
Baseline -,123 ,028 ,009 -,215 -,030 
6 Months ,121 ,035 ,038 ,005 ,236 
9 Months ,219 ,059 ,025 ,025 ,414 
6 Months 
 
Baseline -,244 ,044 ,002 -,388 -,099 
3 Months -,121 ,035 ,038 -,236 -,005 
9 Months ,098 ,051 ,488 -,068 ,264 
9 Months 
 
Baseline -,342 ,073 ,005 -,583 -,101 
3 Months -,219 ,059 ,025 -,414 -,025 
6 Months -,098 ,051 ,488 -,264 ,068 
a - Adjustment for multiple comparison: Bonferroni 
 
 
Table 34: Post hoc test comparing ALSFRS-R in each assessment 
(I) 
ALSFRS-R 
(J)  
ALSFRS-R 
Mean 
Difference 
(I-J) 
Std. 
Error 
Sig.ª 
95% Confidence 
Interval for 
Differenceª 
Lower 
Bound 
Upper 
Bound 
Baseline 
 
3 Months ,016 ,016 1,000 -,034 ,067 
6 Months ,130 ,020 ,000 ,064 ,196 
9 Months ,212 ,042 ,003 ,074 ,350 
3 Months 
 
Baseline -,016 ,016 1,000 -,067 ,034 
6 Months ,114 ,027 ,011 ,025 ,203 
9 Months ,195 ,041 ,004 ,061 ,329 
6 Months 
 
Baseline -,130 ,020 ,000 -,196 -,064 
3 Months -,114 ,027 ,011 -,203 -,025 
9 Months ,082 ,045 ,594 -,066 ,229 
9 Months 
 
Baseline -,212 ,042 ,003 -,350 -,074 
3 Months -,195 ,041 ,004 -,329 -,061 
6 Months -,082 ,045 ,594 -,229 ,066 
a - Adjustment for multiple comparison: Bonferroni 
 
 
 
 
Table 35: Post hoc test comparing MRC in each assessment 
(I) MRC (J) MRC 
Mean 
Difference 
(I-J) 
Std. 
Error 
Sig.ª 
95% Confidence 
Interval for 
Differenceª 
Lower 
Bound 
Upper 
Bound 
Baseline 
 
3 Months ,039 ,015 ,162 -,010 ,089 
6 Months ,085 ,015 ,001 ,035 ,134 
9 Months ,105 ,021 ,003 ,036 ,173 
3 Months 
 
Baseline -,039 ,015 ,162 -,089 ,010 
6 Months ,045 ,018 ,174 -,013 ,104 
9 Months ,065 ,018 ,030 ,005 ,125 
6 Months 
 
Baseline -,085 ,015 ,001 -,134 -,035 
3 Months -,045 ,018 ,174 -,104 ,013 
9 Months ,020 ,014 1,000 -,025 ,065 
9 Months 
 
Baseline -,105 ,021 ,003 -,173 -,036 
3 Months -,065 ,018 ,030 -,125 -,005 
6 Months -,020 ,014 1,000 -,065 ,025 
a - Adjustment for multiple comparison: Bonferroni 
 
 
Table 36: Post hoc test comparing APB muscle in each assessment 
(I) APB (J) APB 
Mean 
Difference 
(I-J) 
Std. 
Error 
Sig.ª 
95% Confidence 
Interval for 
Differenceª 
Lower 
Bound 
Upper 
Bound 
Baseline 
 
3 Months ,067 ,104 1,000 -,272 ,407 
6 Months ,253 ,122 ,394 -,148 ,654 
9 Months ,501 ,106 ,005 ,153 ,849 
3 Months 
 
Baseline -,067 ,104 1,000 -,407 ,272 
6 Months ,185 ,125 1,000 -,225 ,596 
9 Months ,434 ,156 ,118 -,079 ,946 
6 Months 
 
Baseline -,253 ,122 ,394 -,654 ,148 
3 Months -,185 ,125 1,000 -,596 ,225 
9 Months ,248 ,094 ,149 -,060 ,557 
9 Months 
 
Baseline -,501 ,106 ,005 -,849 -,153 
3 Months -,434 ,156 ,118 -,946 ,079 
6 Months -,248 ,094 ,149 -,557 ,060 
a - Adjustment for multiple comparison: Bonferroni 
 
 
 
 
Table 37: Post hoc test comparing ADM muscle in each assessment 
(I) ADM (J) ADM 
Mean 
Difference 
(I-J) 
Std. 
Error 
Sig.ª 
95% Confidence 
Interval for 
Differenceª 
Lower 
Bound 
Upper 
Bound 
Baseline 
 
3 Months ,262 ,060 ,008 ,066 ,458 
6 Months ,422 ,093 ,006 ,117 ,726 
9 Months ,545 ,101 ,002 ,213 ,877 
3 Months 
 
Baseline -,262 ,060 ,008 -,458 -,066 
6 Months ,160 ,065 ,196 -,052 ,372 
9 Months ,283 ,074 ,021 ,040 ,526 
6 Months 
 
Baseline -,422 ,093 ,006 -,726 -,117 
3 Months -,160 ,065 ,196 -,372 ,052 
9 Months ,123 ,081 ,969 -,143 ,389 
9 Months 
 
Baseline -,545 ,101 ,002 -,877 -,213 
3 Months -,283 ,074 ,021 -,526 -,040 
6 Months -,123 ,081 ,969 -,389 ,143 
a - Adjustment for multiple comparison: Bonferroni 
 
 
Table 38: Post hoc test comparing BB muscle in each assessment 
(I) BB (J) BB 
Mean 
Difference 
(I-J) 
Std. 
Error 
Sig.ª 
95% Confidence 
Interval for 
Differenceª 
Lower 
Bound 
Upper 
Bound 
Baseline 
 
3 Months ,160 ,060 ,139 -,036 ,356 
6 Months ,180 ,090 ,433 -,113 ,473 
9 Months ,359 ,061 ,001 ,160 ,559 
3 Months 
 
Baseline -,160 ,060 ,139 -,356 ,036 
6 Months ,020 ,058 1,000 -,169 ,209 
9 Months ,199 ,067 ,084 -,021 ,419 
6 Months 
 
Baseline -,180 ,090 ,433 -,473 ,113 
3 Months -,020 ,058 1,000 -,209 ,169 
9 Months ,179 ,077 ,252 -,073 ,431 
9 Months 
 
Baseline -,359 ,061 ,001 -,559 -,160 
3 Months -,199 ,067 ,084 -,419 ,021 
6 Months -,179 ,077 ,252 -,431 ,073 
a - Adjustment for multiple comparison: Bonferroni 
 
 
 
 
Table 39: Post hoc test comparing TA muscle in each assessment 
(I) TA (J) TA 
Mean 
Difference 
(I-J) 
Std. 
Error 
Sig.ª 
95% Confidence 
Interval for 
Differenceª 
Lower 
Bound 
Upper 
Bound 
Baseline 
 
3 Months ,049 ,108 1,000 -,304 ,402 
6 Months ,175 ,117 1,000 -,210 ,559 
9 Months ,353 ,084 ,011 ,076 ,630 
3 Months 
 
Baseline -,049 ,108 1,000 -,402 ,304 
6 Months ,125 ,079 ,856 -,133 ,384 
9 Months ,304 ,077 ,017 ,051 ,556 
6 Months 
 
Baseline -,175 ,117 1,000 -,559 ,210 
3 Months -,125 ,079 ,856 -,384 ,133 
9 Months ,178 ,065 ,123 -,034 ,391 
9 Months 
 
Baseline -,353 ,084 ,011 -,630 -,076 
3 Months -,304 ,077 ,017 -,556 -,051 
6 Months -,178 ,065 ,123 -,391 ,034 
a - Adjustment for multiple comparison: Bonferroni 
 
 
Table 40: Post hoc test comparing EDB muscle in each assessment 
(I) EDB (J) EDB 
Mean 
Difference 
(I-J) 
Std. 
Error 
Sig.ª 
95% Confidence 
Interval for 
Differenceª 
Lower 
Bound 
Upper 
Bound 
Baseline 
 
3 Months ,163 ,149 1,000 -,326 ,651 
6 Months ,384 ,107 ,030 ,033 ,734 
9 Months ,356 ,161 ,306 -,170 ,883 
3 Months 
 
Baseline -,163 ,149 1,000 -,651 ,326 
6 Months ,221 ,148 ,993 -,263 ,705 
9 Months ,194 ,133 1,000 -,244 ,631 
6 Months 
 
Baseline -,384 ,107 ,030 -,734 -,033 
3 Months -,221 ,148 ,993 -,705 ,263 
9 Months -,027 ,137 1,000 -,477 ,422 
9 Months 
 
Baseline -,356 ,161 ,306 -,883 ,170 
3 Months -,194 ,133 1,000 -,631 ,244 
6 Months ,027 ,137 1,000 -,422 ,477 
a - Adjustment for multiple comparison: Bonferroni 
 
 ATTACHMENT B 
 
Muscles included in MRC measurements.
ATTACHMENT C 
 
ALSFRS-R scale in Portuguese. 
 
 
ESCALA FUNCIONAL DA ESCLEROSE LATERAL AMIOTRÓFICA 
(ALSFRS) 
 
1.  Deve ser comparado o estadio actual do doente com o estadio em que 
se encontrava antes do início da doença (e não com o estadio da última 
consulta) 
 
2.  Na escala (de 4 a 0), deve ser registada a resposta à pergunta: “Como é 
que está em relação a ….?” 
 
1. FALA 
 
4 Discurso normal 
3 Perturbações detectáveis no discurso 
2 Inteligível com repetição 
1 Discurso combinado com comunicação não verbal  
0 Perda do discurso útil 
 
 
 
 
 
 
2. SALIVAÇÃO 
 
4 Normal 
3 Ligeiro, mas com excesso de saliva na boca  
Talvez se babe durante a  noite 
2 Moderado excesso de saliva: um mínimo de baba  
1 Marcado excesso de saliva com alguma baba 
0 Marcado excesso de baba: requer o uso constante de um lenço 
 
3. ENGOLIR 
 
4 Hábitos alimentares normais 
3 Problemas prematuros ao comer, com ocasional sufocamento  
2 Alterações na consistência da comida 
1 Necessita de sonda de alimentação suplementar 
0 Não se alimenta pela boca (alimentado exclusivamente por via 
entérica ou parentérica) 
 
4. ESCRITA 
 
4 Normal 
3 Lenta e irregular, todas as palavras são legíveis 
2 Nem todas as palavras são legíveis 
1 Consegue agarrar na caneta mas não é capaz de escrever 
0 Não consegue agarrar na caneta 
 
 5a. CORTAR A COMIDA E MANEJAR OBJECTOS  
(Doentes SEM gastrostomia) 
 
4 Normal 
3 Algo lento e desajeitado mas não precisa de ajuda 
2 Pode cortar a maior parte da comida, embora lento e desajeitado 
necessita de alguma ajuda 
1 A comida tem que ser cortada por alguém mas ainda se consegue 
alimentar lentamente 
0 Necessita de ser alimentado  
 
5b. CORTAR A COMIDA E MANEJAR OBJECTOS   
(Escala alternativa para doentes COM gastrostomia) 
 
4 Normal 
3 Desajeitado mas capaz de desempenhar todas as actividades 
independentemente 
2 Precisa de alguma ajuda para apertar e desapertar o botão de 
gastrostomia  
1 Dá ajuda mínima à pessoa que cuida dele/dela     
0 Completamente dependente 
 
6. VESTIR E HIGIENE PESSOAL 
 
4 Normal 
3 Independente apesar da tarefa requerer esforço e ter eficácia 
diminuída  
2 Ajuda intermitente ou substituição de métodos 
1 Necessita de auxílio para o cuidado pessoal 
0 Total dependência  
 
 
7. VOLTAR-SE NA CAMA E AJUSTAR A ROUPA DA CAMA  
 
4 Normal 
3 Algo lento e desajeitado mas não necessita de ajuda 
2 Pode voltar-se sozinho e ajustar os lençóis, mas com muita 
dificuldade  
1 Pode iniciar mas não voltar-se ou ajustar os lençóis sozinho 
0 Incapaz 
 
8. ANDAR 
 
4 Normal 
3 Prematuras dificuldades ambulatórias  
2 Caminha com ajuda 
1 Apenas movimento funcional, não ambulatório  
0 Sem movimentos úteis dos membros inferiores 
9. SUBIR ESCADAS  
 
4 Normal 
3 Lento 
2 Moderada instabilidade e fadiga 
1 Necessita de assistência 
0 Impossível 
 
 
(10. RESPIRAR) 
 
4 Normal 
3 Falta de ar para ao mínimo esforço (ex. andar, falar)  
2 Falta de ar em repouso 
1 Assistência ventilatória intermitente (ex. nocturna) 
0 Dependente do Ventilador 
 
10. DISPNEIA 
 
4 Normal 
3 Ocorre na marcha 
2 Ocorre num ou mais dos seguintes (comer, tomar banho, vestir-se    
– AVD) 
1 Ocorre em repouso, dispneia quando sentado ou deitado 
0 Dificuldade severa – considera-se uso de ventilação mecânica 
invasiva com entubação ou traqueostomia 
11. ORTOPNEIA 
 
4 Normal 
3 Alguma dificuldade no sono nocturno por dispneia – usualmente não é 
necessário mais que 2 almofadas 
2 Necessita de mais de 2 almofadas para dormir 
1 Apenas consegue dormir sentado 
0 Incapaz de dormir 
 
12. INSUFICIÊNCIA RESPIRATÓRIA 
 
4 Normal 
3 Uso intermitente do BiPAP 
2 Uso contínuo do BiPAP durante a noite 
1 Uso contínuo do BiPAP durante o dia e a noite 
0 Ventilação mecânica invasiva com entubação ou traqueostomia 
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